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Background/Aim: Chimeric antigen receptor (CAR) T-cell therapy is a novel cell therapy for treating 
hematological cancers including multiply relapsed large B-cell lymphoma in adults. Although for some 
patients it can produce long-term remission who would have otherwise run out of treatment options, it is 
very expensive, costing $373,000 U.S. dollars per patient. There are other additional hospital costs related 
to management of severe adverse events. The first two Health Canada approved CAR T-cell therapy 
products were reviewed by the Canadian Agency for Drugs and Technologies in Health (CADTH) and 
recommended for funding. Because CAR T-cell therapies have not been administered before in Canadian 
hospitals, there are certain logistical concerns with implementation that are unique.  
The first aim of this thesis is to describe processes of developing CAR T-cell therapy and administering it 
to patients, as well as describe the challenges to implementation and considerations for long-term 
sustainability of cell and gene therapy in Canada. The second aim is to evaluate the cost-effectiveness of 
axicabtagene ciloleucel, a CAR T-cell therapy for treating adult lymphoma patients, compared to salvage 
chemotherapy. 
Methods: A qualitative interview study was conducted with 13 CAR T-cell therapy stakeholders 
including scientists, clinicians, and policy-makers in Canada. Questions were asked related to CAR T-cell 
therapy development, treating patients, challenges to implementation, and suggestions for logistical 
planning at the healthcare system level. 
A partitioned survival model was developed in TreeAge Pro Software from a Canadian public payer 
perspective. Patients with large B-cell lymphomas were modeled and their health outcomes from being 
treated with axicabtagene ciloleucel or salvage chemotherapy were extrapolated over a lifetime time 





Results: The results from the qualitative interviews were summarized into 4 main themes: novel, patient 
characteristics and experiences, processes from “bench to bedside”, and future state of CAR T-cell 
therapy in Canada, including both challenges and recommendations to ensure sustainability. 
The ICER generated for the cost-effectiveness analysis was $170,380 per QALY. At a willingness-to-pay 
threshold of $150,000 per QALY, CAR T-cell therapy is not cost-effective. There is some uncertainty in 
the long-term efficacy of CAR T-cell therapy and in the cost of CAR T-cell therapy. 
Conclusions: Valuable perspectives from CAR T-cell therapy stakeholders on the current and future state 
of CAR T-cell therapy were highlighted from a Canadian perspective. In addition, a reduction in price of 
CAR T-cell therapy and reduced uncertainty through collection of long-term health outcomes can 
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Introduction and Background 
1.1 Large B-cell Lymphomas   
Large B-cell lymphomas are a type of non-Hodgkin lymphoma in which tumours develop from the rapid 
production of abnormal B-lymphocytes, a type of white blood cell,  in the lymph nodes.1,2 Worldwide, 
Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of NHL, accounting for 30 to 40 
percent of cases.1,2 DLBCL is characterized by lymphocytes that are larger in size than normal lymphocytes, 
and arranged in a diffuse pattern. Other subtypes of DLBCL include primary mediastinal B-cell lymphoma 
(PMBCL) and DLBCL transformed follicular lymphoma (TFL). These types of lymphomas often present 
quite aggressively as advanced stage disease.1,2    
In 2017, it was estimated that there were 8,300 new cases and 2,700 deaths from NHL in Canada.20 In 2019, 
it is estimated that there will be 10,000 new cases and 2,700 deaths from NHL. Although DLBCL can occur 
at any age, most people are diagnosed in their mid sixties.3 In Canada, the five-year net survival rate for 
non-Hodgkin lymphoma is 68%, indicating that about 68% of people diagnosed with NHL will survive for 
at least 5 years, although this varies by prognostic factors such as age and stage of disease.3 
1.2 Treatment Guidelines and Typical Patient Prognosis 
Most patients with DLBCL (approximately 60%) are successfully treated with chemo-immunotherapy as a 
first line therapy, and the remaining (30 to 40%) will likely experience a relapse and require second-line 
therapy.2,4-5 Upon failure of first line treatment, patients will often receive a second chemo-immunotherapy.5 
If patients respond effectively to chemotherapy but their cancer recurs, they may go on to receive high dose 
chemotherapy followed by a stem cell transplant.6-8  
 Approximately half of patients who receive subsequent chemotherapy will fail to achieve a response 





treated with second-line chemotherapy will proceed to a stem-cell transplant.8 About half of patients who 
undergo a stem-cell transplant will relapse.9 Patients who do not respond effectively to these treatments, 
experience resistance to chemotherapy, or relapse again following a stem-cell transplant have very few 
options and a poor prognosis.7  
The median overall survival reported in a retrospective study of 636 patients receiving salvage 
chemotherapy with aggressive B-cell lymphoma that was primary refractory or relapsed less than 12 months 
after autologous transplant was about 6.3 months.10 However, with the development of a novel gene therapy 
called chimeric antigen receptor (CAR) T-cell therapy, relapsed and refractory patients may be able to 
receive a potentially life-saving treatment and go into long-term remission.11-12 CAR T-cell therapy is 
indicated for patients who have relapsed after two or more lines of therapy which include a stem-cell 
transplant, or patients who have refractory disease. If patients do not receive CAR T-cell therapy, they 
would likely only receive supportive care and stop active treatment.6,11-12 
Based on the number of new NHL cases in 2019 and estimated proportion of those patients with DLBCL, 
as well as the estimated percentage of relapsed/refractory patients who were 1) refractory to chemotherapy 
2) ineligible for SCT or 3) relapsed following SCT, it is estimated there could be at least 918 cases in 












Figure 1.1 Estimated number of patients in Year 1 of CAR T-cell therapy available in Canada for adult large B-cell 
lymphoma patients 
 
1.3 CAR T-cell Therapy  
CAR T-cell therapy utilizes a patient’s own T-cells to develop a therapy that targets a specific tumour 
antigen. T-cells are classified as lymphocytes (white blood cells) which have several roles in the body.  
These include recognizing foreign antigens and infections, activating the immune system to attack them, 
and producing cytokines that direct response in other immune cells.13,14 These processes occur through the 
T-cell receptor, which recognizes antigens only when presented on the surface of cells bound to a major 
histocompatibility complex (MHC) molecule.14  In a CAR T-cell, the T-cell receptor is replaced by a 
synthetic engineered receptor, which enhances the T-cell response and recognizes antigens independent of 
the MHC .13 This tumour-targeted recombinant antigen receptor includes an intracellular domain involved 
in T-cell activation and signalling, and an extracellular domain that is specific to a target antigen.15-16 . In 





malignancies, referred to as CD19-postive malignancies.15  The mechanism by which the CAR T-cell 
attacks cancerous cells is through elimination of CD19 expressing tumour through effector and cytolytic 
processes.  When a CAR T-cell recognizes the target antigen, it is activated through its effector function 
and able to kill tumour cells through its cytolytic function.17-18 There are several different generations of 
CAR T-cells, which refer to variations in the intracellular signalling domain, and they grow more complex 
with later generations.14 Second or later generation CARs contain co-stimulatory domains, which improve 
T-cell activation and anti-tumour efficacy.15 The two Health Canada approved products, axicabtagene 
ciloleucel, and tisagenlecleucel, are both second generation anti-CD19 CARs.21 
1.4 Manufacturing CAR T and Administering it to Patients  
CAR T is unique because it is highly personalized, can lead to long-term remission, and comes at a very 
high cost. To develop CAR T-cell therapy, a T-cell sample is required from a patient and is produced 
through a process called leukapheresis. Leukapheresis involves the separation of the components of white 
blood cells and the isolation of T-cells.20  The T-cell sample is then sent to the drug manufacturer where it 
is genetically engineered to express the CD19 antigen. The CAR gene is transfected into T-cells using 
retroviral or lentiviral vectors. The genetically engineered cells are then grown in large numbers in a lab 
and the final product in frozen and sent back to treating centre.20  Patients typically undergo 
lymphodepleting chemotherapy prior to the infusion of the engineered immune cells to improve the success 
of the therapy by reducing the number of competing lymphocytes.15-17,20 Once the patient has received the 
therapy through infusion in a hospital, they must be monitored for severe side effects such as cytokine 
release syndrome (CRS) and neurotoxicity over the next few days to a few weeks.11-12 
1.5 CAR T-cell Therapy Commercialized Products for Large B-cell Lymphomas 
To date, two different CAR T-cell therapy products for refractory large B-cell lymphomas in adults have 
been approved by Health Canada. Axicabtagene ciloleucel is a therapy developed by Kite Pharma (a Gilead 





Canada in early 2019.21  The cost of axicabtagene ciloleucel is $373,000 U.S. dollars.22 The indication for 
this particular CAR T-cell product is adult patients with relapsed or refractory large B-cell lymphoma after 
two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise 
specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising 
from follicular lymphoma (transformed follicular lymphoma, or TFL).21 Tisagenlecleucel is another CAR 
T-cell therapy developed by Novartis which also targets the CD19 antigen, and is indicated for the similar 
adult patient population who have relapsed or refractory DLBCL after receiving at least two lines of 
therapy, as well as for pediatric acute lymphoblastic leukemia.12,21 It was approved by the FDA and Health 
Canada and costs $475,000 U.S. dollars.22  
For use in Canada, both therapies require the T- cell sample to be shipped to the site of the manufacturer to 
be genetically engineered and shipped back to the hospital site delivering the therapy.20 The typical 
turnaround time from manufacturing to infusion is between two to three weeks.11,20 For patients with 
relapsed/refractory disease who have not responded effectively to prior treatments, it is critical to receive 
this therapy in a timely manner, while maintaining stable physical health. 
1.6 CAR T-cell Therapy Efficacy and Safety 
Axicabtagene Ciloleucel  
Axicabtagene ciloleucel, or Yescarta, is a second-generation CD19 CAR T-cell.11 The pivotal clinical trial, 
ZUMA-1, enrolled 7 patients in the Phase 1 trial and 111 patients in Phase 2 with refractory DLBCL, PML, 
or follicular lymphoma, which was defined as progressive or stable disease as the best response to the most 
recent chemotherapy regimen or disease progression or relapse within 12 months after autologous stem-
cell transplantation. In the Phase 2 trial, axicabtagene ciloleucel was successfully manufactured in 110 
patients (99%) and 101 patients received axicabtagene ciloleucel (91%) with median time from 
leukapheresis to delivery of axicabtagene ciloleucel to the treating facility of 17 days.11 Response was 





outcome. At the primary analysis at an median of 8.7 months of follow-up, the objective response rate was 
82% and complete response rate was 54%. At the updated data cut-off at a median follow-up of 15.4 
months, 42% of still patients had a response, including 40% with a complete response. At 8 months, the 
overall rate of survival was 52%. Common adverse events included cytokine release syndrome of 93% of 
patients with most cases being Grade 1 or 2 severity (81%), and neurologic events in 64% of patients, with 
28% being Grade 3 or higher.11 
Tisagenlecleucel 
The Phase II JULIET trial enrolled patients with relapsed or refractory DLBCL who were ineligible for or 
had disease progression after autologous stem-cell transplantation.  There were 111 patients were treated 
with tisagenlecleucel aged 18 years or older with DLBCL, and 93 patients included in the efficacy analysis 
of patients who had 3 months or more of follow-up or had discontinued participation in the study before 3 
months. Prior to receiving the infusion, 92% of patients underwent bridging chemotherapy and 93% 
received lymphodepleting chemotherapy.12 
The best overall response rate was 52%, with 40% of patients having a complete response and 12% having 
a partial response. The most common adverse events of any grade were cytokine release syndrome (58%), 
anemia (48%), pyrexia (35%), decreased neutrophil count (34%), decreased platelet count (33%), decreased 
white-cell count (33%), and diarrhea (32%).12 
The most common grade 3 or 4 adverse events of special interest included cytokine release syndrome 
(22%), neurologic events (12%), cytopenias lasting more than 28 days (32%), infections (20%), and febrile 
neutropenia (14%).12 
CAR T-cell Therapy Adverse Events 
For both CAR T-cell therapy products, the most common Grade 3 or 4 adverse events included cytokine 





response characterized by fever and an elevated level of cytokines. Symptoms of cytokine release syndrome 
include pyrexia, hypotension, hypoxia, tachycardia.11    
 In the JULIET trial, median time from infusion to onset of symptoms of CRS of any grade was 3 days and 
the median duration was 7 days. Patients with CRS in the JULIET trial were treated with one or two doses 
of tocilizumab, as well as other treatments including supportive care, oxygen supplementation, endotracheal 
intubation, high-dose vasopressors and dialysis in a proportion of patients.12 
Neurologic event symptoms can include delirium and confusion, speech disturbances, seizures and focal 
neurological deficits.15 These symptoms can be treated with supportive care including glucocorticoids. In 
the JULIET trial, the median time to onset of neurologic events of any grade was 6 days and the median 
duration was 14 days.12 
CRS and neurotoxicity are common side effects from immunotherapies that most often occur with days to 
two weeks of infusion. However, symptoms can range from mild to life threatening. The majority of cases 
are treated within a few weeks, but there is a risk that symptoms can be severe and life threatening.11  Grade 
3 or 4 CRS or neurotoxicity often requires the patient to be in the intensive care unit (ICU) for up to weeks 
depending on the severity.   Of the patients who had CRS, 24% were admitted to the intensive care unit.   
During the first week post-infusion, patients are monitored closely in the hospital and while side effects are 
treated.23 
Monitoring Post Infusion 
After side effects have resolved, patients will likely have office visits twice a week with a clinician for 1 
month followed by weekly visits for the second month, then ongoing monthly visits.24 After treatment, 
many patients require monthly intravenous immunoglobulin infusions to prevent infections in patients with 
B-cell aplasia, which results from normal B-cell lineage cells being significantly reduced or eliminated 





some patients have experienced a sustained complete response to the therapy at or past 39 months following 
treatment even after CAR cells are no longer detectable.25 
1.7 CAR T-cell Therapy in Drug Regulatory Landscape in Canada 
In Canada, new cancer therapies must undergo several steps in the regulatory and approval process to be 
funded in the provinces. First, a drug must be approved by Health Canada which is based on the available 
safety and efficacy data in the pivotal clinical trial. After a drug or therapy receives a Notice of Compliance 
(NOC) from Health Canada, it will be reviewed by the Canadian Agency for Drugs and Technologies in 
Health (CADTH). Typically, the pan Canadian Oncology Drug Review (pCODR) branch of CADTH 
reviews the clinical evidence, cost-effectiveness, patient perspectives and feasibility of new cancer drugs 
to inform a recommendation made by the pCODR Expert Review Committee (pERC) about whether the 
provinces should fund the therapy for patients. After a recommendation is issued, the pan Canadian 
Pharmaceutical Alliance (pCPA) works to negotiate the price with the drug manufacturer, and each 
province ultimately decides if they will fund the therapy for patients.26 The two CAR T-cell therapies were 
approved by Health Canada based on efficacy and safety data from single-arm trials showing a high 
percentage of complete responses, and then reviewed by CADTH. Because of the unique features of CAR 
T-cell therapy, it was reviewed through the health technology assessment process for medical devices and 
clinical interventions rather than through pCODR.27 CADTH’s approach was to evaluate the clinical 
evidence, and cost-effectiveness in addition to ethical and legal considerations with adoption in Canada and 
summarize the findings in an “Optimal Use Report”. Currently, the Health Canada approved CAR T-cell 
therapy products are not yet widely funded for Canadians and administered in Canadian hospitals except 
for in special circumstances. The reports confirmed that there is a clinical benefit from the therapies and 
some of the unique regulatory, reimbursement and implementation issues were highlighted. 28,29 CADTH 






1.8 Growth of cell and gene therapies 
There has been tremendous growth of the number of clinical trials in the CAR T-cell therapy space. At the 
end of 2016 there were 220 documented CAR T-cell clinical trials, and this number continues to grow.30 
Based on search of ClinicalTrials.gov, there were over 500 ongoing, completed or unknown status clinical 
trials (Phase I to Phase IV) related to CAR T-cell therapy.31 With the first two CAR T-cell therapies 
undergoing the regulatory process in the past two years, government and regulatory agencies have adapted 
their processes to fit the unique and novel features of this therapy.28,29 The majority of clinical trials with 
CAR T-cell therapy are for treating hematological cancers, followed by solid tumours and rare diseases.30 
It is expected that there will be more personalized and high cost treatments will be in the regulatory and 
market access phase as  medicine advances and CAR T-cell therapy will pave the way for others in the 
future. 
1.9 Knowledge Gap and Thesis Objectives: 
There are two important knowledge gaps in the drug current reimbursement context in Canada that will be 
addressed in this thesis. The first is that the capacity of the health care system to support the implementation 
of CAR T-cell therapy Canada is currently unknown. In addition, challenges and barriers associated with 
implementation of regenerative medicines and feasibility of implementation are poorly understood despite 
the momentum that CAR T-cell therapy has gained in the last few years in terms of clinical research. The 
research conducted will provide a better understanding of the current landscape of CAR T-cell therapy 
specific to Canada and the unique challenges the country faces with adoption and implementation.  
The second knowledge gap is that a cost-effectiveness analysis of CAR T-cell therapy for treating adult 
patients with large B-cell lymphomas in a Canadian context has not been published in a journal for research 
intent. There is however a Canadian economic evaluation of tisagenlecleucel in pediatric patients with acute 
lymphoblastic leukemia.32 In 2019, CADTH published the findings from their reviews of axicabtagene 





certain parts of the data supporting the economic analyses are redacted due to confidentiality with the drug 
manufacturers. The conducted economic evaluation will contribute to a health technology assessment 
(HTA) of CAR T-cell therapy in a Canadian context and can be used by decision-makers in the drug 
reimbursement space. 
1.10 Objectives 
There are 2 main objectives of this thesis. 
1. Conduct qualitative interviews to understand processes of developing CAR T-cell therapy and 
administering it to patients and identify challenges to developing and delivering CAR T-cell 
therapy in Canada. 
2. Develop an economic model for CAR T-cell therapy for treatment of adult patients with large B-
cell lymphoma to support decision-making regarding the adoption of this therapy in Canada. 
a. Integrate all relevant evidence including effectiveness, safety, and costs 
b. Project the health and economic burden. 
c. Perform uncertainty analyses and assess the impact on the results. 
 
There is limited literature available about the current and future state of regenerative medicine, 
specifically CAR T-cell therapy in Canada. Determining barriers to implementation and system capacity 
are important to the understanding of the context of where CAR T-cell therapy fits in the bigger picture. 
A Canadian qualitative interview study on this topic is novel and has not been completed to date.  
To determine whether this therapy is a feasible option for certain Canadian patients, it is critical to 
evaluate the cost-effectiveness and the overall impact on the healthcare system. To date, a cost-
effectiveness analysis for axicabtagene ciloleucel in the adult aggressive lymphoma population has not 
been conducted in a Canadian context. The results will provide an evidence-based assessment of the 
projected health and economic burden that CAR T-cell therapy will have in Canada. The proposed 





to support decision-making regarding CAR T-cell therapy treatment in the future. Results of this research 
will provide an overview of the CAR T-cell therapy in a Canadian healthcare system context, and a cost-
effectiveness analysis of CAR T-cell therapy in patients with large B-cell lymphomas from a Canadian 
perspective.   
 
Chapter 1 will address the first objective and describe the qualitative interview study that was conducted. 
Chapter 1 will give an overview of why understanding the processes of developing CAR T-cell therapy 
and administering it to patients from the perspectives of scientists and clinicians in Canada is important. 
The methods for recruiting participants for the study, interviewing them, and analyzing the qualitative 
data will be described. Lastly, the results of the qualitative study will be described through the main 
themes that arose related to the study objectives. 
 
Chapter 2 will give an overview of economic evaluations as part of health technology assessments to 
inform decision-making around funding new drugs. The methods for conducting a cost-effectiveness 
analysis (CEA) of axicabtagene ciloleucel compared to salvage chemotherapy in adult patients with large 
b-cell lymphomas will described in detail, and the results of the base-case analysis will follow. The results 














Certain cell and gene therapies are considered disruptive to the healthcare system because they are highly 
personalized, resource intensive, and very costly per patient. With a number of these therapies recently 
evaluated by policy-makers in Canada and recommended for funding, the anticipated impact on current 
healthcare system capacity is great, requiring hospitals and healthcare professionals with specialized skills 
to develop and deliver them effectively. In Canada, CADTH conducts reviews of new drugs, clinical 
interventions, or health technologies, and makes funding recommendations based on four domains: clinical 
evidence, cost-effectiveness, patient perspectives, and feasibility of implementation.33 Chimeric antigen 
receptor (CAR) T-cell therapy is one of the first disruptive interventions to undergo the regulatory approval 
process in Canada and therefore is not well understood in this context. As discussed in Chapter 1, there are 
currently two CAR T-cell therapy products that have been recommended for funding in the provinces by 
CADTH, tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta). The processes of 
manufacturing CAR T-cell therapy and administering it to patients are unique and have not been described 
qualitatively through views of key stakeholders in a Canadian setting. Although CADTH has published 
some ethical and implementation challenges of CAR T-cell therapies identified by stakeholders in reports34-
35, barriers to the adoption of CAR T-cell therapy in the healthcare system have not been well documented 
or described in a Canadian context.38,39 With more therapies of this nature being developed and undergoing 
clinical trials, it is important to understand current barriers to the adoption and implementation of these 
therapies in the Canadian healthcare system. Qualitative analyses help inform healthcare policy by 
“clarifying the interplay between stakeholders, health systems and context.” In addition, they help us to 






The collective perspectives of CAR T stakeholders including scientists and researchers, clinicians, policy-
makers and regulatory agencies have yet to be described in this context. The purpose of this study was to 
gather qualitative data through interviews with important stakeholders to understand the processes of 
developing CAR T-cell therapy and delivering it to patients, and understand the challenges to the 
widespread adoption of CAR T-cell therapy in the healthcare system.  
2.2 Methods 
This study was approved by the University of Waterloo Research Ethics Board prior to conducting research. 
The consolidated criteria for conducting qualitative research (COREQ) checklist was used for reporting 
results.39 Interview questions were designed to address the purpose of the study and were approved in 
January 2019. The initial interview questions were revised to add additional questions at two different 
points. Questions were designed for the three different target participant groups. These included: scientists 
involved in CAR T manufacturing, clinicians who treat pediatric or adult hematological cancers, and policy 
makers who work in regulation of pharmaceuticals in Canada. Semi-structured interview questions were 
developed to learn about the specific processes of developing CAR T-cell therapy and administering it to 
patients, the patient experience, and the processes of drug regulatory approval. Open ended questions were 
also developed to understand the views of participants on challenges to implementation. Depending on the 
participant’s role they were asked semi-structured questions most relevant to them as well as all open-ended 
opinion questions. Questions were adjusted for policy-makers because of their unique expertise in the drug 
regulatory space. Appendix B1 for the full set of interview questions. 
2.3 Recruitment 
Participants were recruited using a combination of purposive sampling and snowball sampling and were 
initially recruited because of their known role in CAR T-cell related projects. During interviews, the 
participants were asked if they could refer suitable interview candidates and in some cases these individuals 





with four interview confirmations. A reminder email was sent in March to the other 6 people and two more 
interviews were confirmed. A second round of invitation emails were sent in April to 8 more individuals 
resulting in four confirmed participants. Emails were sent out three more times in May, June, and July, 
based on referrals and other known CAR T stakeholders who were not initially contacted. 3 more interviews 
were conducted in this time. After participants confirmed interest in participating, an interview consent 
form was sent out to be signed and returned prior to the set interview date. The consent form can be found 
in Appendix B2. The interview questions were sent out ahead of time so that participants given time to 
prepare answers as some questions required technical responses. Thirteen interviews in total were 
conducted between March and July 2019. 
Figure 2.1. Interview participant recruitment 
 
2.4 Interviews 
One-on-one semi-structured interviews were conducted by video call using Zoom or by phone with audio 
only. Interviews were scheduled for 1 hour and were between 30 minutes and 1 hour in length. Participants 
were notified that they would not be personally identified and only their perspectives would be shared. 
Interviews were recorded using Zoom when this platform was used or with a recording device if by phone. 
Participants were asked a set of questions most relevant to their field: scientist, clinician, or policy-maker. 





role-specific questions were asked, participants were asked open-ended questions about perceived 
challenges to the adoption of CAR T-cell therapy, potential changes in the healthcare system, and broadly 
why CAR T-cell therapy is unique. Interviews were coded throughout the interview process to determine 
when the saturation of ideas and themes was reached. Interviews were stopped after saturation was reached. 
This occurred after 13 interviews. 
2.5 Analysis 
Each interview was transcribed using a transcription service and each participant was given a unique 
identifier using a number and their role in the study as a scientist, clinician or policy-maker. Data analysis 
was completed in four stages: 1) Independent coding by 2 researchers to reduce bias. The interviewer 
and another researcher independently coded 3 transcripts of three different types of participants and met to 
refine codes. Another researcher was consulted to resolve differences in coding schemes. 2) Agreement on 
codes and applying to new transcripts. The 2 researchers agreed on a set of common codes and then 
applied these codes to two more transcripts of the three different participant groups. 3) Finalize codes and 
apply to all transcripts. The two researchers then defined additional codes and finalized the list of codes. 
This set of codes was then applied to all the transcripts using Nvivo qualitative data analysis software. 4) 
Thematic analysis. Related codes were organized into broader themes. 
Deductive coding was used when participants were directly asked questions about certain processes and 
therefore organized in this manner (Eg. Manufacturing process). Inductive coding was used to understand 
responses to open-ended questions and to allow unanticipated themes emerge. After codes were applied to 
all transcripts, the codes were organized into a matrix and a set of themes was generated. Themes were 
created with sub categories aligning with the codes that were applied. 
After ten interviews were conducted, the researchers began qualitative analysis and found that saturation 
was reached through the reiteration of ideas in interviews. Saturation was determined through the repetition 





after conducting 10 interviews, it was determined that saturation was reached. At this point, the research 
questions were able to be answered.40-41 3 more interviews were conducted after this to fill in any gaps 
identified by the primary researcher and to confirm saturation had been reached. Adding additional 
participants did not result in new themes but did help to clarify processes and timelines described for 
developing CAR T-cell therapy and administering it to patients and showed that there was consistency in 
answers about challenges to implementation and suggestions for ensuring long-term sustainability of CAR 
T-cell therapy across the three different participant groups. 







2.6 Participants  
The sample of participants included 3 Scientists/Researchers, 5 Clinicians in hematology, and 5 policy 
makers in the drug regulatory space. All participants were Canadian-based, and their locations were 
recorded. Participants identified as either male or female. Participants were given a unique identifier based 
on their role with the prefix C for clinician, P for policy-maker, and S for Scientist followed by a number 







2.7 Results  
Four key themes were identified through qualitative analysis: 
• Novel: CAR T-cell therapy is novel in many ways; its unique mechanism of action as a gene 
therapy, it is highly personalized, it has a high per patient upfront cost, it can lead to long-term 
survival and remission in patients, and requires significant hospital resources. These characteristics 
make CAR T-cell therapy difficult to classify as a typical drug, but rather a complex clinical 
intervention. 
• Patient characteristics and experiences: This theme includes: characteristics of patients who are 
eligible to receive CAR T-cell therapy based on the Health Canada approved indications, the impact 
of CAR T on patients, the current unmet need for patients who have not been successfully treated 
with previous lines of therapy, and why equitable access to CAR T-cell therapy for patients across 
Canada needs to be considered. 
• Processes from “bench-to-bedside”: There are specific processes and requirements to: effectively 
manufacture a CAR T product for each individual patient, prepare the patient to receive treatment, 
transport the product to the treating facility, and administer the therapy to the patient in a hospital. 
• Future state of CAR T in Canada: This theme is defined as: current barriers and challenges to 
the implementation of CAR T-cell therapy in the healthcare system, suggestions and predictions 
for long-term sustainability of CAR T, ways to enhance and improve existing healthcare programs 
and address current barriers, and planning logistics of implementation of CAR T across Canada. 
 
Novel: 
When asked to describe CAR T-cell therapy in their own words or about why it is unique, participants often 
described CAR T-cell therapy as difficult to classify because it is more than just a drug. One participant 





innovators. In so far as they provide options, fundamentally new ways of treating particular indications. 
They're introduced and delivered in a way that is different from the kind of treatments(…) in terms of the 
complexity. So it's not a drug.” Another participant stated “Well it's unique because it's really a game 
changer, that's one thing. Second of all it's completely different in terms of it's not a drug, at least not as 
we see it presently. It's a cellular therapy, it's got its whole set of complications and its got a significant 
cost. It needs special expertise in terms of manufacturing.” 
CAR T-cell therapy was also described by participants as extremely expensive and highly personalized. In 
addition, participants stated that CAR T-cell therapy offers patients a potentially curative and life-saving 
treatment option where otherwise patients would receive salvage chemotherapy or palliative care, as the 
current Health Canada approved indications are for patients who are relapsed or refractory to two or more 
lines of therapy.  When asked about the most important benefits of CAR T-cell therapy, one clinician stated 
“It's the only chance at cure, or at complete responses. So I think it has the ability to prolong life which is 
what the current regimens for relapsed or refractory disease don't have,” and another clinician stated, “I 
think it's definitely a high priority, based on the emerging evidence thus far and that these patients really 
had the ... the only treatments for these patients before was really palliative care. This is certainly providing 
... the evidence that has come out of the typical trials certainly shows that this therapy is very effective for 
certain patients” 
CAR T-cell therapy was also described by participants as novel in terms of the infrastructure and resources 
required to effectively deliver CAR T, and that it poses a unique challenge with ensuring equitable access 
across Canada with CAR T requiring such a specialized expertise to develop and deliver. Policy makers 
emphasized that it will be a challenge to ensure patients across the country can get access to this therapy 
due to the specialized resources and personnel required. They felt that not every province would be able to 
deliver the therapy, therefore it was important to consider how patients across Canada could access CAR 
T-cell therapy equitably.  On equity, a participant stated, “there have been a lot of discussions around 





issue because of the fact that... because of how it's supposed to be delivered, because of expertise required, 
because of the infrastructure that's required.”  
Although many participants commented on CAR T-cell therapy being novel in some way, participants also 
recognized that the complexity of delivering CAR T-cell therapy equitably is similar to a bone marrow 
transplant, which has set a precedent for CAR T-cell therapy. Participants felt that CAR T-cell therapy is 
similar in terms of the resources required in comparison to some existing interventions, with one participant 
stating, “It's more similar to administering stem cell therapy where it's kind of a stem cell transfer versus 
administering chemo.” 
Patient characteristics and experiences 
Clinicians were asked to describe patients who would be eligible to receive CAR T-cell therapy based on 
the current Health Canada approved indications and their general characteristics in their own words. The 
current approved indications are for pediatric and young adults with acute lymphoblastic leukemia (ALL) 
who are refractory, have relapsed after allogenic stem cell transplant (SCT) or are otherwise ineligible for 
SCT, or have experienced second or later relapse; and for the treatment of adult patients with relapsed or 
refractory large B-cell lymphoma after two or more lines of systemic therapy.  Participants indicated that 
these patients do not have other treatment options and a poor prognosis. One clinician stated, “For 
refractory ALL, it actually is causes disease remission and for refractory lymphoma, likewise. That's kind 
of a big important thing. It meets an unmet need.” Clinicians described patients as very sick but must be 
physically well enough to survive until the CAR T-cell manufacturing process of a few weeks is completed 
to receive the therapy. One participant said, “You have to make sure that the patient can ... these very sick 
patients can withstand that timeline, in order to create therapy for them, in order to be able to be well 
enough to receive that therapy.” 
Patients must also be able to provide a sufficient cell sample for the CAR T-cell product to be developed 





explained that patients would be treated with chemotherapy in the weeks leading up to the infusion. One 
clinician’s response summarized this, stating, “The challenge is to just give them just enough chemotherapy 
to keep them well, but not enough that you make them sick and land them in the hospital or get them and 
result in an infection, because that all delays getting to the CAR T-cells.” 
After being infused with CAR T-cell therapy, which was described as a straightforward inpatient procedure, 
patients are monitored for side effects. Clinicians discussed two common side effects that can be life 
threatening and require immediate treatment: CRS and neurotoxicity, which occurred in most of the patients 
in the pivotal clinical trials for the two Health Canada approved CAR T-cell products.  When summarizing 
these adverse events, one clinician said, “…It all depends on what it is. If we're talking about, let's say, 
cytokine release syndrome. I said 80% develop it. Then it depends what kind of degree you have. If you 
have a grade 1, if you just have a fever, this is something that, yes, you would admit the patient but just to 
a regular ward. If that's all they have then that's it. If they have higher degrees of CRS then they may need 
ICU care, they may need (vaso)pressors, they may need to be on the ventilator, they may need 
dialysis…Neurotoxicity, same thing. Sometimes they just get hallucinations... but that is something you just 
watch and you don't do much. Again, that would be a regular ward kind of scenario. We have seen patients 
who become completely encephalopathic and need ICU care. That's the other extreme of that. Again, it 
depends on the severity of the symptoms.” 
These side effects can occur within days of the infusion and last from days to almost two weeks, with one 
participant reporting, “systematic reviews say it's about five or seven days with CRS and seven to twelve 
days for neurotoxicity”. Clinicians noted that depending on the severity of the symptoms, some patients 
will need to be in the intensive care unit (ICU) short-term, around “30 to 40%” of patients.  
Clinicians indicated that patients would be heavily monitored during the first week after the infusion as an 
inpatient and treated for side effects if they occur. After the first week of heavy monitoring, clinicians would 
likely see the patient every week for a few weeks after the patient returns home, and monthly for a few 





developed that, then I'd say 10 days they'd probably go home. Their ongoing follow-up, remember these 
are our patients with active malignant would be once or twice a week in clinic, blood count checks, like 
that, for the rest of the month, and then less frequently if they're doing well.” 
However, as the Health Canada approved CAR T-cell products have not yet been funded for use in Canada 
in certain hospitals, some clinicians only had knowledge and experience with the patient receiving the 
treatment in the United States and returning to Canada following the resolution of side effects. Once the 
therapies are funded, they will be administered to patients in Canadian hospitals. 
Processes from “bench to bedside” 
One of the primary outputs from the interviews were detailed descriptions of processes including 
manufacturing CAR T-cells and administering the therapy to patients in the hospital. These descriptions 
included things such as steps to complete processes, length of time, personnel and resources required, and 
errors that can occur. These processes were organized into a flowchart showing how CAR T-cell therapy is 
developed and how it is administered to the patients. Participants described manufacturing CAR T-cells in 
two contexts: academia and industry. In academia, CAR T-cell products are developed at academic centres 
for research and product development and for clinical trials. In industry, there are two commercial products 
that have been approved by Health Canada that are developed at the manufacturing sites of the drug 
companies Novartis and Kite Pharma (a Gilead Sciences company) in the United States.21 Participants 
described the process of leukapheresis, the collection and isolation of white blood cells from a blood sample 
to be used to create the CAR T product. A patient will give a blood sample and machine will isolate the 
white blood cells. This can be done at a hospital facility in Canada with the proper resources to generate 
the cell sample and deliver the therapy and was described as a “routine process”. The cell sample is then 
transported to the manufacturing facility, where the processes of reengineering the cells by combining the 
cell sample and the lentivirus and growing them in large numbers occur to produce the final product. With 
commercial products, the final CAR T-cell product is frozen and sent back to the treating hospital in some 





the therapy in the United States. The average time for manufacturing the individualized product reported 
by participants ranged from three to four weeks, with an average of 17 days reported by Kite Pharma in the 
clinical trial for axicabtagene ciloleucel for patients with DLBCL. Researchers developing products in 
Canada noted that the manufacturing turnaround time is around two weeks. In addition, participants 
discussed that to develop a functional CAR T-cell therapy product, a Good Manufacturing Practice (GMP) 
facility is required, which includes a rigorous process to ensure employees are trained properly and that 
quality standards are met for products. Participants with experience in manufacturing were also asked to 
discuss errors that could occur in manufacturing that would lead to a failure, which occurred in a small 
percentage of patients in the clinical trials for tisagenlecleucel in pediatric ALL and axicabtagene ciloleucel 
in DLBCL. A participant stated “So you know, the 7% manufacturing failure that we saw with Novartis 
when the studies were published, that was because (they) couldn't expand enough cells to make it a viable 
CAR T product. Nowadays the manufacturing failures are often related to the functionality of the product,” 
indicating that although errors can still occur, the cause of them has changed over time. 








Future State of CAR T in Canada - Challenges 
Participants were asked about current challenges to effective implementation of CAR T-cell therapy in 
Canada and asked about for their recommendations ensure long-term sustainability of CAR T-cell therapy. 
Some key challenges identified were:  
• the high cost of CAR T to the healthcare system and maintaining funding 
• limited capacity of manufacturers and hospitals to develop and deliver CAR T 
• government and regulatory agencies working with short-term efficacy data and having to make 
decisions for the future with limited evidence 
Challenge 1 - High Cost to Healthcare System 
Participants noted that not only is the cost of CAR T-cell therapy products very expensive, there are many 
additional hospital costs associated with CAR T-cell therapy. The cost for the approved CAR T-cell 
products ranges from $373,000 USD to $475,000 USD.22 Because administering CAR T products to 
patients is new to Canadian hospitals, clinicians noted that patients would likely be admitted as an 
inpatient in the days leading up to the therapy and may stay in the hospital for 1 to 2 weeks. Some 
patients who experience serious adverse events may need to be transferred to the intensive care unit (ICU) 
which also increases costs. Summarizing this theme, one participant stated “Well, the biggest challenge is 
clearly the costs associated with it, right? The commercial products that are coming out of the US 
companies have costs of hundreds of thousand dollars per product on top of the actual clinical treatment 
costs are associated with that.”  
Challenge 2 – Limited Capacity 
Across all areas of expertise, participants felt that one of the largest barriers to implementation is capacity. 
Participants spoke about capacity in the context of the current healthcare system not currently being able to 
meet the demand for CAR T-cell therapy. Participants agreed that even if CAR T-cell therapy were 





clinicians noted is similar to CAR T-cell therapy in terms of the hospital resources required. Hospitals with 
expertise in bone marrow transplants were discussed by participants as being the best equipped to 
effectively deliver CAR T. Participants were concerned about the number of patients that would eligible 
for CAR T and the limited hospital resources, specifically regular ward beds and ICU beds. One participant 
stated “Everything you need to treat these complicated patients as we’re short of. And we’ve been working 
to improve that, so we’re just sort of catching up on the transplant side and then these guys came along”, 
and another saying “at this point, we don’t have enough bed space in the province to meet the need for the 
number of patients who would be eligible for CAR-T in the province” referring to Ontario. 
Challenge 3 – Limited Evidence 
Based on interview responses, “limited evidence” is defined as short-term efficacy data for the approved 
CAR T-cell therapy products. Participants discussed that decisions are being made at the government level 
about funding and implementation of CAR T-cell therapy based on data from single-arm clinical trials that 
ranged from 14 to 27 months of follow-up.11,12 It was noted that cost-effectiveness and value for money is 
important when using healthcare budget dollars for innovative cancer therapies. Working with limited data, 
participants shared that there is some uncertainty in the long-term benefit and cost-effectiveness of CAR T, 
although early data is very promising and suggests many patients can go into long-term remission. A quote 
illustrating this theme is “…we also don’t have long term data on the products that are currently marketed. 
And so when you try to do planning at a system level it becomes very difficult because you’re not planning 
for today or even the year after, you’re trying to plan five to 10 years down the road. So trying to estimate 
the numbers of patients that would require this therapy and then the proper resources as far as health 
human resources, capital infrastructure… to care for these patients and what their long term needs might 
be is quite difficult. So, the costs of not just purchase of the CAR T-cell but the cost of the actual care and 
management of these patients, there is limited information to go on. Even the clinical trials that have 





breast cancer, or so forth. That’s a big challenge for us in the planning phase.” This quote shows the 
challenge of working short-term data to make long-term decisions about healthcare. 
Future State of CAR T-cell Therapy – Planning at the System Level 
Responses to many questions focused on recommendations for sustainability of CAR T-cell therapy and 
other cell and gene therapies. These fell under three main categories: 
• Coordination among stakeholders 
• Implement infrastructure, training and education 
• Consider reimbursement strategies and cost-effectiveness 
• Adapt to emerging evidence 
Recommendation 1 – Coordination Among Stakeholders 
Participants discussed the need for CAR T-cell therapy stakeholders to be aligned to ensure patients can get 
timely and maintained access to CAR T-cell therapy. Key stakeholders include government and regulatory 
agencies, industry, clinicians, hospitals, and patients. 
A quote illustrating this is “I think the manufacturer working with the provinces to achieve a price that’s 
equitable, sustainable for the success of CAR T. The first step. I think that’s one. In terms of other steps to 
maintain or improve the success, or sustainability of the treatments, I think we need to continue with 
research, which we’re doing. It can’t stop with these three indications, or two indications that exist in the 
market. If the technology is going to be sustainable, you need the evidence to support funding it.” Another 
participant stated, “I have to say that my perception is that there's a lot of people on the various levels that 
are involved being in politics, being in health administration, being at the hospitals, that there's a lot of 
good will, enthusiasm to make this happen.” Participants felt that there is a will by CAR T-cell therapy 






Recommendation 2 – Implement Infrastructure, Training and Education 
Participants recognized that infrastructure is an important consideration regarding which hospitals would 
be best suited to deliver CAR T-cell therapy and what resources are required. Most participants agreed that 
there is already some infrastructure in place that can be built upon. For example, participants reported that 
establishing centres of excellence that are accredited through the Foundation of Accreditation for Cellular 
Therapy (FACT) will be required to effectively deliver CAR T-cell therapy. FACT is a globally recognized 
standard for hospitals that do stem cell transplants and treat patients with other cellular therapies.42 To 
summarize these points, a participant stated, “In terms of treating patients, a lot of the infrastructure 
already exists, so if sites administer, for example, allogeneic stem cell transplant, a lot of these procedures 
already exist to accommodate CAR T therapies. It's one of the main reasons why some of the first centers 
that we approach are the FACT certified center. They have the infrastructure, for the most part, to 
accommodate these therapies.” Along with infrastructure comes training and education within 
manufacturing facilities and hospitals. Participants agreed that safely and effectively delivering CAR T-cell 
therapy in the hospital requires specific training as illustrated by one participant stating, “I think in Canada 
what we need to do is get the infrastructure in place, which we're beginning to do now, get the training ... 
It'd take a lot of training to get people up to speed so the technicians who run the machines, the people who 
... the docs who give the treatment. They have to become familiar with what to expect and how to treat it 
and so on, and all that has to be built”.  
Recommendation 3 – Consider Reimbursement Strategies and Cost-Effectiveness 
Another key area for system-level planning was reimbursement. While funding was mentioned as one of 
the most prominent challenges, it was noted that provinces will have to make decisions about which budget 
the funding for these therapies will come from for reimbursement. When describing the regulatory 
processes for evaluating a new cancer drugs and pricing negotiations, a participant stated, “So, in essence, 
all of that is the same for CAR T except who is actually funding it. It's a bit different depending on the 





whether it may come out of something else. That's a bit of a challenge, and a bit of a uniqueness to this 
particular product. And I'm not really sure entirely whether every single province and territory have sorted 
out exactly where the money or the funding is going to come from”. Some participants also discussed the 
importance of establishing value-for-money for CAR T-cell therapy before making a large investment and 
novel solutions to implementation issues may be required. Summarizing this, one participant said “In terms 
of sustainability, I think again, we have to do everything we can to negotiate the prices down as far as we 
can to make sure that, because we do have limited healthcare dollars, and we're in a socialized medicine 
environment, we do need to make sure that we're using our money wisely. And so, if we can negotiate the 
prices down, and maybe even come up with novel ways of administering the therapy. So, like, maybe moving 
it to the out-patient setting in the hospitals, could result in less cost to the tax payer.”  
Recommendation 4 - Adapt to Emerging Evidence  
Participants discussed that while there are two Health Canada approved indications for CAR T-cell 
therapies at present, there are many more being developed and tested which should be accounted for in 
long-term planning. Participants discussed new indications for CAR T-cell therapies and gene therapies, as 
well as clinical trials for CAR T-cell therapy used in earlier lines of therapy. Participants also discussed 
that as the eligible patient population grows, the healthcare system needs to be able to manage the increased 
capacity and adapt to emerging evidence. A quote illustrating this is “I think we have to change our mindset 
and say we have to deliver these drugs, or these therapies, in a different way. We have to approach it 
differently because they're gonna continue to evolve. This is not the end. This is the very ... I'm gonna sound 
very Churchill-like. This is the end of the beginning. We really are beginning to see these expand and if you 
keep going at it in a one-at-a-time in the sort of side-level approach of pharma, it'll take 50 years”. Thinking 
ahead, participants recognized that in its current state, the healthcare system is not fully prepared to 
implement CAR T-cell therapy for the approved products for the anticipated number of patients.  A 
participant shared, “But, having said that, if in fact the indications stand and grow and CAR T becomes 





just a handful of sites in the province, or in the country to do this. So, where should we be planning and 
how should we be training these individuals for this therapy?”. 
Many participants discussed the need for the healthcare system to consider more than just what is happening 
today in the CAR T-cell world, but what is to come, if Canada is going to adopt other innovative therapies 
in the future. Participants were hopeful that eventually CAR T-cell therapy could be an outpatient procedure 
which would reduce costs.  In addition, a few participants discussed the idea of CAR T-cell therapy being 
manufactured within Canada at academic or research hospital centres rather than solely by manufacturers 
because of the evolving nature of CAR T-cells. On the topic of an outpatient model, a participant stated 
“U.S. institutions who have done this a bit longer than we have actually are working with an outpatient 
model. That's where we are going as well. Then once the patients develop signs of side effects, then that's 
the time when you would admit them, but not routinely admit them just because they got CAR T cells.” On 
the topic of developing CAR T-cell products in Canada and the evolution of CAR T cells, one scientist 
stated “There is a push to,…to allow centers that have bone marrow expertise but are not necessarily set 
up for GMP labs, to have a manufacturing facility to actually make these CAR T-cells on machines that you 
can just put in your lab as we normally do, for cell sorting during the transplant process and in a way like 
that, produce CAR T-cells that meet all the criteria to be given to a patient.” Another participant stated 
“The other thing that we need to mention is not just that the CAR T-cells are being investigated for other 
diseases, but also the particular CAR T product itself is undergoing a revolution. First generation, second 
generation, et cetera, et cetera, and that impacts what the future might look like. Whether the costs will 
change, whether the risk benefit will change, and so forth.”  
2.8 Discussion 
The results of this study highlight the challenges that policy-makers face with the implementation of CAR 
T-cell therapy in the Canadian healthcare system. The qualitative interviews led to the development of four 
key themes: novel, patient experiences with CAR T-cell therapy, processes from “bench to bedside” and 





long-term sustainability. Participants consistently described CAR T-cell therapy as novel in terms its 
therapeutic benefit and the way it is developed and administered to patients. In addition, participants 
focused on the patient experience living with acute lymphoblastic leukemia or large B-cell lymphoma and 
their experiences with CAR T, focusing on two common but serious adverse events: cytokine release 
syndrome and neurotoxicity. With both scientist and clinician perspectives, processes ranging from 
collecting cells and manufacturing CAR T-cell therapy in a lab to administering the therapy in the hospital 
and monitoring patients were described in detail. Lastly, participants in all fields outlined key barriers to 
implementation including high drug cost and hospital costs, and that many hospitals currently lack the 
capacity to effectively deliver an additional resource intensive therapy. Participants commented on the 
future of CAR T-cell therapy in Canada, giving recommendations for planning at the system level, and 
looking ahead to what is next in the cell therapy space. To facilitate implementation of CAR T-cell therapy, 
participants noted that alignment and coordination with stakeholders, tailored training and education at 
hospitals, and establishing cost-effectiveness and negotiating a fair price are all important.  
Currently, there is an unmet need for relapsed or refractory pediatric ALL patients and adult LBCL patients 
and CAR T-cell therapy is a potentially life-saving treatment for eligible patients. There are challenges to 
delivering this high-cost and novel therapy across Canada, however, the interviews illustrated that from the 
perspective of participants, stakeholders are working together to ensure the long-term sustainability of CAR 
T-cell therapy and other novel therapies. 
The results presented in this study align with other reports on challenges with implementing CAR T-cell 
therapy in the healthcare system, although they have not been described qualitatively through interviews in 
a Canadian context. In the Optimal Use reports published by CADTH for the approved CAR T-cell therapy 
products, ethical, legal, and implementation issues were highlighted as part of a comprehensive review. 
CADTH highlighted views from stakeholders about how to roll out the delivery of CAR T-cell therapy. 
This included stakeholder views on manufacturer oversight of treatment sites, accreditation of treatment 





highlighted key ethical consideration which included: balancing safety and effectiveness of the therapies, 
ensuring equitable access across the country and equitable patient selection, high cost of CAR T-cell 
therapy, patients having an informed choice of treatment options, and the burden of going through treatment 
on the patient and their caregivers and families.34-35 
2.9 Limitations 
This study had several limitations to be noted. Although saturation was reached, there was a small sample 
size of 13 participants (3 scientists/researchers, 5 clinicians, 5 policy-makers). In addition, this study did 
not include patients, who are at the centre of discussions about CAR T-cell therapy. Future research would 
benefit from the patient perspective on their own experiences with CAR T-cell therapy and their views on 
challenges to implementation. Another limitation is that the majority of participants (12) were from Ontario 
with only 1 participant from British Columbia. The perspectives are limited to the experiences of 
participants in these areas and may not be generalizable to the perspectives across all of Canada. This was 
the case due to certain national drug regulatory agencies located in Ontario, the leadership demonstrated by 
Ontario and British Columbia with developing CAR T-cell therapy products, and the location of currently 
specialized hospital centres in delivering cell and gene therapies. 
2.10 Conclusions 
The goal of this study was to understand challenges to the implementation of CAR T-cell therapy in Canada 
and the various processes involved in developing CAR T-cell therapy and administering it to patients from 
the perspectives of key CAR T-cell therapy stakeholders. Participants included scientists, clinicians and 
policy-makers. Their views highlighted unique challenges to Canada to the successful implementation and 
adoption of CAR T-cell therapy in the healthcare system, and some challenges that have been reported 
previously. Canada-specific views on barriers to implementation and recommendations for planning at the 





perspectives of Canadian patients and their experiences with accessing CAR T-cell therapy before and 




















Cost-effectiveness of CAR T-cell Therapy in Adults with Relapsed 
or refractory Large B-cell Lymphoma from a Canadian Perspective 
 
3.1 Background 
With the two FDA and Health Canada approved CAR T-cell therapy products having such a high cost per 
patient, it is important to establish cost-effectiveness of CAR T-cell therapy when compared to standard 
treatment. As discussed in Chapter 1, patients would likely receive salvage chemotherapy after experiencing 
multiple relapses or being refractory to treatment. Establishing cost-effectiveness of new cancer therapies 
ensures that limited healthcare dollars are providing value-for-money.43 Cost-effectiveness is determined 
using the incremental cost-effectiveness ratio (ICER), which is the cost per additional quality-adjusted life 
year (QALY) gained.42 QALYs are a measure of both the quantity and quality of health and allow for health 
interventions to be compared using a “common currency”.44 If a treatment is at or below a certain 
willingness-to-pay threshold, it is commonly considered to be cost-effective. A WTP threshold of $50,000 
is not explicitly by CADTH but is often used as a benchmark in economic evaluations and is cited in many 
of their economic reports.45 Specific to the pan Canadian Oncology Drug Review process, there are cases 
of therapies being approved with an ICER of up to $140,000 per QALY based on an evaluation of pCODR 
recommendations between 2011 and 2017.46 
As many cancer therapies are covered through public provincial drug plans for Canadians, it is appropriate 
to conduct a CEA from the perspective of the Ministries of Health in the provinces. To conduct a CEA in 
patients with large B-cell lymphomas, the eligible patient population can be simulated moving through the 
health states of progression-free, progressed and death. The probability of being in these health states can 
be informed by the progression-free survival (PFS) and overall survival (OS) curves of patients treated with 
CAR T-cell therapy and with standard treatment from published clinical trial data. This structure is called 





in part because PFS and OS are commonly measured and reported outcomes of clinical trials for cancer 
therapies to determine efficacy.47 
Utility values between 0 and 1 are assigned to the progression-free, progressed, and death health states, 
where 0 is death and 1 is perfect health.44 These utility values allow the incremental QALYs gained or lost 
to be calculated. As patients move through these health states, costs occur at the time of treatment and 
throughout follow-up care and monitoring. Costs are not limited to the costs of the therapies, but can also 
include hospital costs, adverse event management, office visits and consultations for follow-up care, and 
subsequent treatments.43 
Figure 3.1. Partitioned survival model structure 
 
3.2 Previous Published Cost-Effectiveness Analyses of CAR T-cell Therapy for 
Adults with Large B-cell Lymphomas 
In the “Optimal Use” report published by CADTH in which a health technology assessment of CAR T-cell 
therapies was conducted, one component was an economic evaluation. The economic evaluation compared 
axicabtagene ciloleucel to best supportive care. This model was developed by the manufacturers and 
submitted to CADTH for review. CADTH reviewed and critiqued the economic models and provided 





model was a partitioned survival model (PSM) with three health states, and the baseline patient 
characteristics were based on the ZUMA-1 trial.28 
In the CADTH reanalysis of the economic evaluation of axicatagene ciloleucel, CADTH reported that the 
total costs of axicabtagene ciloleucel were $626,104 and $106,415 for BSC leading to an incremental cost 
of $519,689. The total quality-adjusted life years gained for axicabtagene ciloleucel was 4.47 and 2.17 for 
BSC leading to incremental QALYs of 2.30. The incremental cost-effectiveness ratio was $226,131 per 
QALY gained.28,29 Limitations of the manufacturer’s model noted by CADTH were: the lack of head-to-
head trials between comparators, lack of generalizability of the ZUMA-1 patient population median age in 
the real-world clinical setting, the time at which patients were considered cured and were considered to 
have a similar risk of death than a general Canadian population, not censoring patients treated with 
subsequent therapies, uncertainty in PFS data for BSC due to a lack of available data, and uncertainty in 
some cost values. Key assumptions made in CADTH’s reanalysis were the adjustment of the average age 
to be 67 rather than 58 in the manufacturer’s original submission, using an assumption that patient who 
remain progression-free for five years instead of two years are considered cured, and that the cured 
population has a higher risk of death of than the general Canadian population. 
Other CEAs have also been published from a U.S. third party payer perspective comparing axicabtagene 
ciloleucel to salvage chemotherapy between 2018 and 2019.48-50 In a CEA published by Lin et al in 2019, a 
state-transition model was developed to assess the cost-effectiveness.  At 40% 5-year PFS, axicabtagene 
ciloleucel resulted in an additional 3.72 QALYs at a cost of $129,000 per QALY ($89,000 to $219,000 per 
QALY) gained compared with salvage chemoimmunotherapy,  however, at 30% 5-year PFS, axicabtagene 
ciloleucel resulted in an additional 2.96 QALYs at a cost of $159,000 per QALY ($105,000 to $284,000 
per QALY) gained, with fewer QALYs and greater ICERs at lower percentage of patients cured.48 In 
another U.S. CEA published by Roth et al in 2018 that utilized a PSM, the reported incremental cost was 
$380,184, incremental effectiveness was 6.54 QALYs leading to an ICER of $58,146.49 Besides the 





regimen selected for comparator, data used to inform efficacy, efficacy extrapolation methods, utilities used 
for health states, and adjustments made to account for patient differences in the clinical trials. 
3.3 Economic Evaluation Model of CAR T-cell Therapy Compared to Salvage 
Chemotherapy in Adult Patients with Large B-cell Lymphomas 
Comparators 
This study compared treatment strategies for adult large B-cell lymphoma patients. In the primary analysis, 
axicabtagene ciloleucel was compared to salvage chemotherapy in patients with multiply relapsed or 
refractory lymphoma. Axicabtagene ciloleucel was chosen as the drug of interest because of its 
demonstrated efficacy in the clinical trials and the lack of published CEAs from a Canadian perspective. 
There is currently no standard treatment for multiply relapsed LBCL, however patients would likely receive 
salvage or palliative chemotherapy. There are several chemotherapy combinations that may be used for 
salvage chemotherapy including: rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDP), as well 
as rituximab, dexamethasone, cytarabine and cisplatin (R-DHAP), and less commonly rituximab, 
isofamide, carboplatin, etopisode (R-ICE).5 A Canadian clinical pharmacist in hematology and bone 
marrow transplantation was consulted to understand estimations of the proportion of patients who would 
receive each of these combinations and it was determined that R-GDP is the most common in the Canadian 
setting for adult patients with LBCL. 
3.4 Methods – Model Structure and Key Model Inputs 
Type of Economic Analysis 
This analysis conducted was a cost-utility analysis with cost-effectiveness assessed by the incremental cost 
in Canadian dollars per quality-adjusted life year gained and is from a publicly funded healthcare payer 
perspective (the Ministries of Health in the provinces in Canada). One-way sensitivity analyses were also 





Economic Evaluation of Health Technologies, and the model used a lifetime (30 year) time horizon to 
capture all meaningful costs and effects.43 A lifetime time horizon is appropriate as the goal of therapy is 
long-term remission and therefore capture costs over a long period of time.43 
The analysis assessed the cost-effectiveness at willingness-to-pay thresholds of $50,000 per QALY, 
$100,000 per QALY, $150,000 per QALY, and $200,000 per QALY. Most costs used in the model were 
taken from Canadian sources apart from the price of the CAR T-cell therapy, axicabtagene ciloleucel, which 
were converted from U.S. to Canadian dollars. The U.S. prices of axicabtagene ciloleucel was sourced from 
the Micromedex Redbook using the wholesale acquisition price and converted to Canadian dollars using 
the Purchasing Power Parity (PPP) using the ratio of the prices of a good or service paid in the U.S. 
compared to Canada in 2018.51 All other costs were adjusted to 2019 Canadian dollars using the Consumer 
Price Index (CPI) from Statistics Canada for health and personal care when required. Specifically, the 
annual national average CPI for all of Canada was used to calculate the costs used in the model.52 
A partitioned-survival model (PSM) was developed using the TreeAge Pro 2019 software package. 
Baseline parameters for the assumptions, costs, and utilities are provided in Table 1. 
Target Population 
The population in this analysis included patients with large B-cell lymphoma who are refractory to or have 
experienced relapse after at least two lines of prior therapy. The mean age of the modeled population is 58 
years based on the median age in the pivotal trial for axicabtagene ciloleucel (ZUMA-1).11 
Model 
A PSM was used to represent three health states a patient with LBCL can be in, which includes progression-
free, progressed, and death. Patients could experience adverse events in the first cycle of the model and 
costs of adverse events were applied in this cycle. At 5 years, patients who remained in the progression-
free or progressed health states state were considered to be in long-term remission. It was assumed that past 





progression-free at 5 years did not experience subsequent progression. This was based on 2 studies that 
assessed long-term outcomes in patients with DLBCL and the low probability of progression past this 
point.53-54 The probability of death of the general population was sourced from the 2015-2017 Statistics 
Canada Life Table for males.55 
In the model, each cycle is 1 month in length. In addition, a patient could only be in one health state at a 
time and they could not move back to a previous health state. Patients in any of the health states could 
progress more quickly than the standard model and move into the death state. 
3.5 Assumptions 
Costs 
Total costs included for the axicabtagene ciloleucel arm of the comparison included wholesale acquisition 
cost of the drug, cost of pre-treatment, cost of leukapheresis, cost of hospitalization for 16 days, cost of 
drug administration by a physician, costs of adverse events, and cost of monitoring including office visits. 
Primary data sources for costs included the Ontario Case Costing Initiative, Canadian Institute for Health 
Information hospital data, Schedule of Benefits and Fees for Physician Services, and the Ontario Drug 
Benefit. Sources for costs can be found in Table 1. Costs of drugs where the dose is weight-based were 
calculated using an average body surface index (BSA) of 1.7m2.56 
Utilities  
Utility values for the progression-free and progressed health states came from quality-of-life data collected 
from a safety management cohort from the ZUMA-1 trial using the EQ-5D-5L instrument.57 The EQ-5D-
5L instrument allows patients to self report their through answering questions in five domains. Patients can 
select one of five options for each question ranging from no problems to extreme problems related to five 





In the quality-of-life study, a total of 34 patients with relapsed/refractory LBCL treated with axicabtagene 
ciloleucel were initially part of the study, with a median follow-up of 5.1 months. The mean EQ-5D-5L 
index was 0.80 (SD = 0.14) for progression-free health state and 0.72 (SD = 0.17) for progressed disease.57 
Adverse Events 
Adverse events experienced by patients in the ZUMA-1 and JULIET trial that were Grade 3 or higher in 
greater than 10% of patients were included in the model.11,12 A cost was applied for the proportion of 
patients that experienced. Adverse event costs were obtained from the Ontario Case Costing Initiative.58 A 
utility decrement was not applied for these adverse events. Key adverse events associated with axicatagene 
ciloleucel included pyrexia (14%), neutropenia (78%), anemia (43%), thrombocytopenia (38%), febrile 
neutropenia (31%), hypotension (14%) encephalopathy (21%), and white-blood cell count decreased 
(29%).  
Cytokine release syndrome (CRS) was included for 13% of patients treated with axicabtagene ciloleucel.11 
For the duration of the first 2 cycles the utility for patients with CRS was 0.56 Patients with Grade 3 or 4 
CRS were estimated to be in the intensive care unit (ICU) for an average of 6 days for axicabtagene 
ciloleucel.28 The average cost of a day in the ICU was obtained from the Canadian Institute for Health 
Information and was based on the average per diem ICU cost in Ontario.60 The cost of 2 doses of 
tocilizumab was also included in the CRS cost. 
For salvage chemotherapy, adverse events were not reported in the trial used for efficacy data, so it was 
assumed that the adverse events that occurred and the proportion of patients matched the adverse events of 
a clinical trial in which transplant-ineligible patients with refractory/relapsing B-cell lymphoma received 
“Gem-Ox”61. Gem-Ox is a salvage chemotherapy combination of gemcitabine and oxaliplatin.61 This was 
used as an assumption in the CADTH Economic Review Report of tisagenlecleucel in adult LBCL patients 






3.6 Methods – Efficacy  
To estimate efficacy of each treatment option over a lifetime time horizon, a method reported by Guyot et 
al62 was used to generate patient-level data from published Kaplan-Meier survival curves from clinical 
trials. In this report, an algorithm was used to reconstruct survival curves using digital software, which 
allowed the use of various survival distributions to be tested to extrapolate survival over a lifetime time 
horizon.62  PFS and OS curves from the long-term follow-up of the ZUMA-1 trial63 (median of 27.1 months) 
for axicabtagene ciloleucel and OS curve from the SCHOLAR-1 trial for salvage chemotherapy10 were first 
reconstructed using the Plot Digitizer computer application. The SCHOLAR-1 trial only reported the OS 
and not the PFS. To generate an estimated PFS curve for salvage chemotherapy, it was assumed that the 
ratio of the PFS curve to the OS curve was proportionate to the ratio PFS and OS curves in the ZUMA-1 
trial at each time point.49 
The PFS and OS curves were uploaded to Plot Digitizer and manually replicated by using the mouse to 
click along the curve to produce a table of the data points for probability of remaining progression-free and 
probability of death for the follow-up period. The PFS curve shows the probability of progressing over time 
in months and the OS curve shows the probability of death over time in months.47 To address human error 
during the clicking process, an Excel function was used to look for data points that did not follow the correct 
ascending or descending order and were removed. The data points of the PFS and OS curves were then 
processed in R software to generate the best fitting parametric survival distributions to predict longer term 
outcomes. Parametric survival analysis techniques are “designed to allow the characterization and summary 
of the observed time-to-event distributions in the form of mathematical models (or equations) that reflect 
the patterns of change in the risk of the events of interest”. These distributions can be used to predict longer 
term outcomes beyond the length of follow-up from a clinical trial.64-66 
A range of parametric survival models were fitted to the reconstructed survival curves, and the selection of 
the most appropriate parametric function for each one was based on visual inspection and plausibility, 





(BIC), and clinical rationale.66 The tested parametric survival models for data extrapolation included 
Loglogistic, Weibull, Lognormal, Gamma, and Exponential.  
The best fitting distribution for each PFS and OS curve for axicabtagene ciloleucel, the OS curve for salvage 
chemotherapy, and the estimated PFS curve data for salvage chemotherapy were used in the analysis. The 
SCHOLAR trial collected data up to 15 years. To allow for the parametric distribution to more closely 
match the first 3 years of data for the OS curve for patients treated with salvage chemotherapy, only data 
up to 3 years was used to generate the extrapolated curve. The parametric distributions were extrapolated 
for 5 years, based on the assumption that the cancer is cured and at this point the probability of progression 
or death stops decreasing and remains constant. The data points for the extrapolated were exported to tables 
and used in TreeAge to estimate patients moving from progression-free to progressed and from progressed 
to death. The fitted parametric distributions for each survival curve are shown in Appendix 3A,3B and 3C. 
The selected parametric distributions are shown in the table below for OS and PFS for axicabtagene 
ciloleucel and for OS for salvage chemotherapy. 
To calculate the patients in the progressed health state, the function is OS-PFS and to calculate those in the 




One-way sensitivity analyses were conducted on all variables by varying the point estimate of each 
parameter by +/- 25%Typically, one-way sensitivity analyses should be conducted using the 95% 
Confidence Interval, but when these values are not known, lower and upper values for all parameters should 
still be assessed67. The cure point was also included in the sensitivity analysis and was varied from 2 to 5 
years before a patient experiences the same probability of death as the general population.  In addition, the 





for OS for salvage chemotherapy were tested in one-way sensitivity analyses.  The top 15 values influencing 
the ICER were reported in a tornado diagram. Because the cost of CAR T-cell therapy in Canadian dollars 
is a highly uncertain value, it was tested at different values in one-way sensitivity analyses. These included 
price increases and decreases based on the base-case price used.  
Based on the economic report by CADTH evaluating axicabtagene ciloleucel in adult patients with LBCL, 
several limitations were noted in the manufacturer’s model and addressed by CADTH in sensitivity 
analyses or in their reanalyses. One parameter that CADTH tested in a sensitivity analysis was the starting 
age in the model. The manufacturer’s model used 58 years based on the ZUMA-trial, but CADTH noted 
that the mean age of Canadian patients with this disease may be higher and used in a sensitivity analysis.  
Probabilistic Sensitivity Analysis 
A probabilistic sensitivity analysis (PSA) was conducted using a Monte Carlo simulation with 10,000 
iterations. A PSA utilizes statistical distributions for each parameter rather than point estimates to account 
for uncertainty in values.42 Costs used a Gamma distribution, probabilities (including PFS and OS patient-
level data as well as proportions of patients experiencing adverse events and receiving SCT) used a beta 
distribution, utilities used a beta distribution, and other time related variables such as the average age and 





Table 3.1 Assumptions, Costs, Probabilities, Utilities 
Parameter Value Source Year Distribution 
Total regular ward hospital days 
during treatment 
16 Qualitative interview study (assume in 
hospital for 2 weeks plus 2 days before for 
pretreatment) 
2019 Normal 
Total ICU days 6 CADTH Report - axicabtagene ciloleucel in 
adult DLBCL 
2018 Normal 
Monitoring Office visit every day for 2 
weeks and then once a week up 
to 1 month followed by once a 
month visit up to 3 months, and 
PET scan at 3 months, 6 
months, 1 year and yearly up to 
5 years 
Interviews 2019  
Costs 
Parameter Value Source Year Distribution 
Leukapheresis $2,508.00 Ontario Case Costing Initiative 2017/2018 Gamma 
Administration of CAR T $105.15 Ontario Physician Schedule of Benefits and 
Fees, Code G359 for special single agent or 
multi agent therapy with major toxicity-
require frequent monitoring 
2016 Gamma 
Administration of chemo $75.00 Ontario Physician Schedule of Benefits and 
Fees, Code G345 for a complex single agent 
or multi agent therapy with potential for some 
toxicities needing intervention by physician 
2016 Gamma 
Pre-treatment - Axicel $212.67 Product monograph (fludarabine and 











  Costs continued   
Parameter Value Source Year Distribution 
Axicabtagene ciloleucel 373,000 USD→ 
$464,385 CAN  
U.S. List Price converted to CAN using PPP 2017 Gamma 
Salvage chemotherapy (R-GDP for 6 
cycles of 21 days) 
21470.14 Dose from BC Cancer Protocol for R-GDP for 
Lymphoma and Myeloma and costs from 
ODB 2019 (hospital pharmacist) 
2019 Gamma 
Hospital day (regular ward) $1851.40 CIHI Patient cost estimator (Intervention with 
Lymphoma)-Ontario - All Lymphoma -adults 
age 18-59 
2017/2018 Gamma 
Hospital day (intensive care unit) $3,710.00 CIHI - Ontario Provincial Average of ICU 
cost per diem 
2017 Gamma 
Office consultation, hematology $157.00 Ontario Physician Schedule of Benefits and 
Fees, Code A615 
2016 Gamma 
PET Scan $1,506.20 TRIUMF, The Use of Positron Emission 
Tomography  (PET) for Cancer Care Across 
Canada Time for a National Strategy 
2011 Gamma 
Stem cell transplant $155,611.00 CADTH Economic Report of axicabtagene 
ciloleucel: Ministry of 
Health and Long-Term Care 
Interprovincial Billing Rates for 
Designated High Cost Transplants 
2019 Gamma 
Complete blood count $3.98 OHIP Schedule of Laboratory Services 2019 Gamma 
Terminal care for lymphoma- 12 
months 
$59,202.00 de Oliveria et al. Phase specific and lifetime 
costs of cancer care in Ontario 
2009 Gamma 
Bridging chemo $19,816.24 CADTH Report 2019 Gamma 
Tocilizumab 2452.80 Dose from axi-cel product monograph (2 
doses, costs from Ontario Drug Benefit) 
 
2019 Gamma 





Parameter Value Source Year Distribution 
Febrile Neutropenia $6,776.00 OCCI 2017/2018 Gamma 
Infections $350.00 OCCI 2017/2018 Gamma 
Pyrexia $424.00 OCCI 2017/2018 Gamma 
Neutropenia $507.00 OCCI 2017/2018 Gamma 
Anemia $8,150.00 OCCI 2017/2018 Gamma 
Thrombocytopenia $436.00 OCCI 2017/2018 Gamma 
Hypotension $560.00 OCCI 2017/2018 Gamma 
White-blood cell count decreased $433.00 OCCI 2017/2018 Gamma 
Encephalopathy $4,055.00 OCCI 2017/2018 Gamma 
Probabilities 
Proportion of patients receiving 
bridging chemo 
Tisagenlecleucel 92% JULIET trial 2019 Gamma 
Axicabtagene 
ciloleucel 
0% ZUMA-1 trial 2017 Gamma 
Proportion of patients getting SCT 
after therapy 






Salvage chemotherapy 29.9% 
 
Axicabtagene ciloleucel proportion with Grade 3-4 adverse events 
Anemia 43% ZUMA-1 trial 2017 Beta 
Febrile neutropenia 31% ZUMA-1 trial 2017 Beta 
Encephalopathy 21% ZUMA-1 trial 2017 Beta 
Hypotension 14% ZUMA-1 trial 2017 Beta 
Neutropenia 78% ZUMA-1 trial 2017 Beta 
Pyrexia 14% ZUMA-1 trial 2017 Beta 
Thrombocytopenia 38% ZUMA-1 trial 2017 Beta 









Progression-free health state 0.75 Health Utilities for Patients with Relapsed or 
Refractory Large B-Cell Lymphoma (R/R-
LBCL): Ad Hoc Analysis From an 
Axicabtagene Ciloleucel (Axi-cel) Safety 
Management Study 
2018 Beta 
Progressed health state 0.72 Health Utilities for Patients with Relapsed or 
Refractory Large B-Cell Lymphoma (R/R-
LBCL): Ad Hoc Analysis From an 
Axicabtagene Ciloleucel (Axi-cel) Safety 
Management Study 
2018 Beta 
CRS Disutility  -0.13 over 2 cycles (utility of 0 
for the first 2 months after CAR 
T treatment is assumed) 
CADTH Economic Report, Lin et al Cost-
effectiveness of  
 
Beta 











The projected PFS and OS curves were validated by comparing the original patient-level data obtained from 
the published survival curves to the R projection using parametric survival distributions and to the TreeAge 
projection. The model generated survival curves that closely match the patient-level data from the clinical 
trials. These analyses are shown in appendix C4, C5 and C6. 
Base-case Analysis 
In the base-case analysis, axicabtagene ciloleucel led to an additional cost of $165,266 and additional 
effectiveness of 3.10 QALYs. This led to an ICER of $170,380. At willingness-to-pay thresholds of $50,000 
per QALY and $100,000 per QALY, and $150,000 per QALY, CAR T-cell therapy is not cost-effective 
based on the base-case analysis. 
Table 3.2 Base-case analysis 



















$693,173 $527,907 4.86 3.10 $170,380 
 
In the base case analysis, at 5 years, 17% of patients treated with axicabtagene ciloleucel remain in the 







One-way sensitivity analyses 
A tornado diagram representing the top variables that impact the ICER in either direction from the base 
case ICER is displayed in Figure 3.3 The top 5 variables were the average age of patients in the model (the 
starting age in the model), the cost of axicabtagene ciloleucel, the utility for progression-free, the utility for 
progressed, and the cure point.  
As the price of CAR T-cell therapy was determined be one of the top variables impacting the ICER, a 
threshold analysis was conducted to determine at what price axicabtagene ciloleucel would have to be to 
achieve an ICER of $100,000 per QALY. At a cost of $246,320, which is a 52% reduction in price, the 
ICER would be $100,000 per QALY.  






Assuming that patients are cured prior to 5 years in remission,  effectiveness of CAR T-cell therapy is 
improved in the model which is reflected in the  ICER. The results are shown in Table 3.3. The average age 
was increased to 67 and tested in a one-way sensitivity analysis in Table 3.4, and higher led to a higher 
ICER due to a decreased health from CAR T-cell therapy. Lastly, the second-best fitting parametric 
distributions to extrapolate long-term PFS and OS for CAR T-cell therapy and OS for salvage chemotherapy 
were tested. The Log-logistic distribution was the second-best fitting distribution based on the curve with 
the second lowest AIC and BIC statistics. The impact of the using the Log-logistic curve rather than Log-
normal was the greatest for CAR T-cell therapy OS and led to an increased ICER. The impact of using the 
Log-logistic curve rather than Log-normal for CAR T-cell therapy PFS and salvage chemotherapy OS was 
minimal. The results of this are shown in Table 3.5. 














at 5 years 
Cure at 2 years 
in remission 
$539,118 3.59 $149,967 48.9% 46.7% 
Cure at 3 years 
in remission 
$536,873 3.49 $154,039 38.5% 37.2% 
Cure at 4 years 
in remission 
$532,325 3.28 $162,143 31.6% 30.8% 
 
Table 3.4 Increased Average Age to 67 


































ICER (Cost per 
QALY) 
Change from Base 
Case 
CAR T – OS (Log-
logistic) 
$521,333 2.80 $185,986 $15,606 
CAR T – PFS (Log 
logistic) 
$527,571 3.09 $170,755 $375 
Salvage 
chemotherapy – OS 
(Log-logistic) 
$527,907 3.10 $170,380 - 
 
Probabilistic Sensitivity Analysis 
To account for uncertainty and ensure robustness in the results, a PSA was run with 10,000 iterations and 
the results are shown in Table 3.6. The results showed that in 90% of iterations, the ICER was above a 
$50,000 per QALY. In 89% of iterations, the ICER was above $100,000 per QALY and 0.43% below 
$150,000 per QALY. In 77% of iterations the ICER was above $150,000 and 13% less than $150,000 per 
QALY and in 56% of iterations were above $200,000 per QALY and 34% of iterations were below 
$200,000. At all willingness-to-pay thresholds, 10% of iterations resulted in CAR T-cell therapy being 
inferior in terms of effectiveness. 
In the PSA, uncertainty in the efficacy data was accounted for by sampling values from a lower and upper 
bound of the mean values over time based on the extrapolated PFS and OS curves. The results of the PSA 
showed that the incremental cost was $497,105 and the incremental QALYs were 1.88 leading to an ICER 
of $264,418. In the PSA, the incremental cost ranged from $331,766 to $607,409, the incremental QALYs 





A PSA was also run with uncertainty in efficacy excluded and the results are shown in Table 3.7. The results 
showed incremental costs of $523,436, incremental QALYs of 3.03 leading to an ICER of $172,751 per 
QALY, which is greater than the base case ICER by only $2,371. 
Table 3.6 Probabilistic sensitivity analysis 













$178,428  2.38   
CAR T (Axicabtagene 
ciloleucel) 
$675,533 $497,105   
 
4.26 1.88 $264,418 
*Incorporates uncertainty in the extrapolated PFS and OS curves for CAR T-cell therapy and salvage 
chemotherapy 
 
Table 3.7 PSA excluding uncertainty in PFS and OS 
 













$164,348  1.73   




4.76 3.03 $172,751 
*Uses base case extrapolation of PFS and OS for CAR T-cell therapy and salvage chemotherapy 
3.8 Discussion 
CAR T-cell therapy has the potential to improve many patients lives by inducing long-term durable 
remission in patients who have run out of treatment options, despite the high cost for the therapy and 
hospital costs. 
The results of the CEA show that CAR T-cell therapy is not cost-effective in adult patients with large B-
cell lymphomas based on the current estimated price and the current published efficacy data at a 





health outcomes are improved for patients including more complete responses and fewer adverse events, 
the ICER will improve and CAR T-cell therapy may become cost-effective. This result is consistent with 
the findings of the economic evaluation by CADTH, and with results reported by Lin et al the United 
States.48 Based on the deterministic base case analysis, the cost of CAR T-cell therapy would have to be 
reduced by 52% to meet a willingness-to-pay threshold of $100,000 per QALY. As more data is published 
on efficacy of axicabtabgene ciloleucel including real world outcomes, it should be incorporated in further 
economic evaluations to ensure value for money is achieved based on longer-term data.  
With an assumption of cure only at or past 5 years in progression-free or progressed health states as in the 
base-case, CAR T-cell therapy is not cost-effective. However, if it is assumed that patients are cured at 2 
years and it is highly unlikely that they will relapse beyond this point, then the ICER decreases to $149,967 
per QALY, which would be cost-effective at a WTP threshold of $150,000 per QALY. 
When uncertainty was incorporated through a probabilistic sensitivity analysis, the mean ICER was higher 
than the deterministic ICER by $94,038, indicating that there is some variability in the parameter values 
and that the ICER may in fact be even higher. 
In this patient population, CAR T-cell therapy was initially rejected by the United Kingdom’s National 
Institute of Health and Care Excellence because it was too expensive, but after negotiating the price with 
Gilead Sciences, LBCL patients are now able to receive CAR T-cell therapy through the National Health 
Service in England. In Canada, axicabtagene ciloleucel and tisagenlecleucel were recommended by 
CADTH provided that there are clear eligibility criteria, interprovincial agreements to ensure equitable 
access, and the collection of real-world evidence data about patients’ outcomes for future reassessment of 
safety, efficacy and cost-effectiveness.68 
With more cell and gene therapies expected to be undergoing the approval process in Canada in the near 







A limitation of the model is that the efficacy data from two single-arm trials for CAR T-cell therapy and 
salvage chemotherapy were compared directly as though the comparators were a in head-to-head clinical 
trial. This resulted in differences between the two patient populations that were not accounted for in the 
model. Because of the lack of comparative trials of CAR T-cell therapy, this was considered appropriate to 
use in the model. Another limitation is that the SCHOLAR-1 trial used for OS data for salvage 
chemotherapy did not report PFS and a method proposed by Roth et al to generate an artificial PFS curve. 
The PFS data used was generated by assuming a proportional ratio of OS to PFS as in the ZUMA-trial and 
actual reported PFS data from the SCHOLAR trial is not available.  
Uncertainty in certain parameters is another limitation of this analysis. Highly uncertain values include the 
actual Canadian cost of axicabtagene ciloleucel, the number of years at which a patient can be considered 
cured or in long-term remission, and the long-term efficacy of CAR T-cell therapy. To account for this 
uncertainty, sensitivity analyses were conducted on these parameters. Uncertainty in long-term efficacy 
was tested in one-way sensitivity analyses by using the second-best fitting distributions for the extrapolation 
of survival curves, and was incorporated into the PSA. 
Additional limitations of include that neurotoxicity was not explicitly included in the model. However, a 
one-time cost for cancer-related death was included which incorporates some palliative costs. It was 
assumed that patients who experience Grade 3-4 CRS and receive ICU care account for the costs from 
neurotoxicity as well. The cost of palliative care was also not included in the model, but it was assumed 
that because both the CAR T-cell therapy and standard treatment arm would have palliative care costs that 
it does not impact the model. There was also a one-time cost of death from cancer which is expected to 
include some palliative care costs. 
In addition, the included adverse events for salvage chemotherapy were based on another trial in which 





was based on the published economic report of tisagenlecleucel comparted to salvage chemotherapy in 
adult LBCL patients by CADTH. The manufacturer’s model used the trial to estimate proportions of 
patients with adverse events treated with salvage chemotherapy although CADTH noted that this is not an 
appropriate assumption because it does not match the salvage chemotherapy in the model. However, the 
SCHOLAR-1 trial did not report adverse events so an exception was made to include this data to account 
for some patient adverse events that could occur from salvage chemotherapy. 
3.9 Conclusion 
The results of this cost-effectiveness analysis compared axicabtagene ciloleucel to salvage chemotherapy 
and produced an ICER beyond a WTP threshold of $150,000 per QALY. With efficacy data on CAR T-
cell therapy limited to around 2 years, there is uncertainty with predicting long-term health outcomes of 
patients. The cost-effectiveness of CAR T-cell therapy depends heavily on the price of the drug itself and 
the expected long-term health benefit. At a lower price and with a higher cure rate, the ICER is improved. 
Overall, CAR T-cell therapy does offer a health benefit over salvage chemotherapy. As with other cancer 
therapies, federal and provincial agencies in Canada will work to negotiate fair pricing with 
manufacturers to ensure patients can access therapies. Although the base-case analysis showed that CAR 
T-cell therapy is not cost-effective, it has the potential to become cost-effective with collection of data on 
long-term patient outcomes and with a reduction in price. For multiple relapsed or refractory lymphoma 
patients, CAR T-cell therapy may be their only treatment option and has been very successful in some 
patients. Canada may consider novel pricing and reimbursement strategies to ensure patients can get 
access to CAR T-cell therapy and that the cost-effectiveness is re-evaluated when more data is available 










4.1 Summary of Results 
The results of Chapter 2 show the views of key CAR T-cell therapy stakeholders in Canada on the processes 
of developing a CAR T-cell product, how to administer CAR T-cells to a patient, and the patient experience 
with B-cell lymphoma after relapsing or being refractory to treatment. The results of the qualitative study 
also highlight some of the unique challenges to Canada with the implementation of a highly personalized 
and expensive-to-deliver therapy, and considerations for the future of novel cell and gene therapies entering 
the Canadian healthcare system. There were 4 key themes that arose from the analysis of qualitative data: 
novel, patient experiences with CAR T-cell therapy, processes from “bench to bedside” and the future of 
CAR T-cell therapy in Canada including challenges to implementation and considerations for long-term 
sustainability. Describing the landscape of CAR T-cell therapy for treating cancer in a Canadian context 
qualitatively allowed for rich description of processes and situations and avoided oversimplification of 
them. The findings from this study can be used to inform policy-makers in Canada and other countries and 
the public about logistical and feasibility concerns with implementing CAR T-cell therapy and other cell 
and gene therapies. As the first two CAR T-cell therapy products have been undergoing the approval 
process throughout 2019, this is a new area to be studied and was previously not well described in the 
literature. 
The results of Chapter 3 show that CAR T-cell therapy is not cost-effective even at a willingness-to-pay 
threshold of $150,000 per QALY. The ICER in the deterministic base-case analysis was $170,380 per 
QALY. Therefore, the price of CAR T-cell therapy would have to reduced by over 50% using the base case 
analysis assumptions for CAR T-cell therapy to be cost-effective at a WTP threshold of $100,000 per 
QALY. While the best available data was used in the analysis to compare CAR T-cell therapy to salvage 





only 27 months of follow-up data on patients treated with axicabtagene ciloleucel was available. The 
probabilistic analysis was able to incorporate uncertainty into the analysis and showed that the mean ICER 
was higher than the deterministic value by $94,038 When making decisions based upon short-term clinical 
trial data and uncertain model parameters, it is important to incorporate uncertainty in models to ensure the 
results are consistent and robust. These results indicate that more data is needed on the long-term health 
outcomes from CAR T-cell therapy to reduce uncertainty in the results.  
4.2 Thesis Contributions 
Currently, there are no qualitative interview studies using interviews that have investigated the opinions of 
Canadian CAR T-cell therapy stakeholders on the logistical concerns of the implementation of CAR T-cell 
therapy or other novel cell and gene therapies in Canada. With the excitement surrounding novel cancer 
gene therapies and the potential for curative treatments, it is also important to understand the reality of 
Canadian approval and regulatory landscape. As the Canadian government must work within a constrained 
budget to deliver healthcare, there are many considerations when approving high cost personalized 
therapies, and value-for-money is important. This study highlights many of these important considerations 
and provided insight into the high-level planning that is required before allowing novel therapies to be used 
across Canada. Although there are some similarities to the U.S. in terms of some of the challenges to 
effective implementation of CAR T-cell therapy, Canada’s single-payer system, and the ongoing CAR T-
cell therapy product development within Canada outside of the drug manufacturer’s lead to a unique 
situation that has not been well described in the literature. 
The CEA comparing axicabtagene ciloleucel to salvage chemotherapy in adult patients with LBCL 
demonstrated that even at willingness-to-pay threshold of $200,000 per QALY, when accounting for 
uncertainty in efficacy data, CAR T-cell therapy is not cost-effective at the present wholesale acquisition 
price. This study confirms what CADTH reported in their published economic evaluation report of the same 





the ICER can change greatly. In addition, it was determined that there is a great deal of uncertainty in the 
efficacy data supporting the approval of axicabtagene ciloleucel. 
4.4 Future Work 
Future work related to understanding processes of developing CAR T and delivering it to patients as well 
as well understanding challenges to implementation would benefit from the patient perspective. Due to time 
constraints, patients were not interviewed as part of the qualitative study. However, it is important to engage 
with patients throughout the different stages of healthcare research to ensure they are heard, and their needs 
are being met. In addition, this study was conducted prior to the widespread use of CAR T-cell therapy in 
Canada. A qualitative study to understand processes of obtaining CAR T-cell therapy products and 
administering them to patients post implementation will provide insight into the real challenges in Canadian 
hospitals and whether anticipated challenges are in fact the actual challenges seen. 
The accuracy of the cost-effectiveness analysis would be improved with reduced uncertainty in specific 
parameters. For example, longer follow-up for efficacy data for CAR T-cell therapy will reduce uncertainty 
in the long-term health outcomes as a result of CAR T-cell therapy. In addition, a head-to-head trial between 
CAR T-cell therapy and the most appropriate comparator would reduce uncertainty in the efficacy data 
from the comparison between two single-arm trials. If collection of this data is not feasible, uncertainty in 
efficacy data could also be improved by using administrative databases once CAR T-cell therapy has been 
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Table A1. Qualitative interview questions 
Interviewee Questions 
Scientist 1. Describe the process of obtaining a T-cell sample from a patient who 
will undergo therapy. 
Follow up questions: 
o Describe the resources and health professionals that are 
required for this process. 
o How long does it take to obtain a sample? 
2. Is your lab/facility able to manufacture CAR T-cell therapy? 
3. Based on your knowledge, how many facilities/labs in Canada can 
produce CAR T-cell therapy (other than the manufacturer)? 
o What is the capacity of these centres? (Number of patients?) 
o How many hospitals in Canada /Ontario can administer the 
therapy? 
4. Based on my understanding, CAR T-cells are generated from a 
patient’s blood sample, which is then genetically engineered to express 
a certain antigen.  
Describe the process of generating CAR T-cells at your facility/centre. 
Probe, if needed: (If/when sent to the manufacturer, what steps must be 
completed first, and which steps does the manufacturer complete? 
Follow-up questions: 
o What resources and health professionals are required for this 
process? 
o Where is the therapy manufactured? 
o What is the typical turnaround time from leukapheresis to 
infusion? 
5. Can errors occur during the manufacturing process? 
o Could you estimate the percentage or number of patients who 
undergo leukapheresis but do not receive a CAR T infusion? 
o What are the reasons why a patient may not receive an infusion 
after initiating the process to receive treatment? 
o Could you estimate the manufacturing failure rate? 
6. What do you estimate the average time (or wait time) is for: 
o Leukapheresis? 
o Manufacturing of cells (time from cells sent to centre for 
manufacturing and sent back to treatment facility) 
o Transport from facility with cell sample to manufacturing 
facility, then from manufacturing facility to treatment centre  
o Infusion once the therapy is transported to the treatment centre 
7. What are the challenges with developing the therapy for use? 
Clinician 1. Describe the standard (s) of care of treatment that would be used if a 
patient was not able to receive CAR T-cell therapy. (Probe: What 
combination of chemotherapy drugs?) 
Follow-up questions: 
o What are the most important benefits of CAR T-cell therapy 
compared to standard therapy? (How many rounds of treatment 
is required for CAR T?) 
o What are the differences? Or disadvantages? (Probe: cost?) 
2. Where does CAR T-cell therapy fit in to the current clinical treatment 





3. What are the most common and serious side effects and how are they 
managed? 
4. Describe the types of patients who are eligible to receive CAR T-cell 
therapy? (Probe: Patient and disease characteristics, age, sex, stage, 
type of cancer, previous treatments) 
Follow-up questions: 
o Is there a specific subgroup? What percentage of patients do 
you estimate are eligible of the patients with (aggressive 
DLBCL or ALL)? (Or do you know where I could find this 
information?) 
o Which patient group should be prioritized to receive this 
therapy? 
o How many patients are there with DLBCL/ALL in Canada? 
(Or do you know where I could find this information?) 
o What is the typical prognosis for a patient with aggressive 
DLBCL/ALL (at initial diagnosis, and following the trajectory 
to be eligible for CAR T ?) 
5. My understanding is that a patient may receive chemotherapy while 
waiting to get CAR T, and they may need to remain close to the 
treatment centre. Can you describe what happens during the period of 
time while a patient is waiting to receive CAR T? (Treatment, travel, 
how long will they have to wait) 
6. Describe the process of administering the treatment to the patient 
Follow-up questions: 
o Where is it done? (E.g. Hospital) 
o Who administers the therapy? 
o How long does the treatment take? 
o How long is patient monitored during administration? 
o Which health care providers are involved? 
o What resources are required? 
o What errors have you seen occur with administering CAR T-
cell therapy? 
7. What does follow-up look like during treatment (after infusion) and in 
the following weeks? (Inpatient versus outpatient care, when they leave 
the hospital)? 
Follow-up questions: 
o How many days are required in the hospital? How many days 
in the ICU? 
o Are there any adverse events that significantly impact length of 
stay in the hospital?  
o After the patient leaves the hospital how are they monitored? 
How many office visits are required? 
o Are patients required to be close to a treatment centre after 
they leave the hospital? And for how long? 
o Could you compare monitoring and follow-up of patients who 
have received CAR T-cell therapy to those that would receive 
the standard of care? 
o If a patient progresses after treatment, how is this handled? 
8. Which processes (developing therapy, delivering it, monitoring/side 
effects, administration) use the most resources? How does this differ 





9. Could you estimate the number of hospitals/centres in Canada or 
Ontario that can administer CAR T-cell therapy? (Number of 
patients/beds?) 
If clinician is familiar with all processes: 
10. Can you describe the process of 1) obtaining T-cells from the patients, 
2) genetically engineering the cells, and 3) administering the therapy to 




1. Describe your understanding of CAR T-cell therapy from a system-
level perspective. (Economic, reimbursement, policy, healthcare) 
2. Describe the role that you have for CAR T-cell therapy in the Canadian 
healthcare system. 
3. What are the challenges to providing CAR T-cell therapy in Canada? 
(Probe: Policy angle, clinical angle) 
4. Based on your knowledge of cancer drug reimbursement, how would 
CAR T-cell therapy fit within the current budget for cancer therapies in 
Canada? (Probe: Is it much different than other cancer drugs? Do you 
anticipate it to be a high priority? Will it displace other drugs?) 
5. Compare CAR T-cell therapy to other novel treatments such as other 
cancer drugs. What is unique about CAR T in the context of drug 
reimbursement, the approval process, and pricing?  How will this be 
assessed and managed for CAR T? What path is CAR T likely to 
follow for coverage? 
o Are there any treatments that have been approved that are similar 
to CAR T-cell therapy in terms of its novelty, cost, and potential 
for long-term survival? 
6. Could you estimate the average time for reimbursement approval by 




Thinking about CAR T from a system level… 
1. What do you expect the biggest challenges to be with adopting this 
new therapy? (Or with each area of the process) 
2. What do you think may need to be changed for this therapy to be 
adopted in Canada? (Or do you think there is anything?) 
3. How does therapy differ than what is currently done? (How is it 
unique) 
4. From your perspective, to implement CAR T in Canada effectively, 
what do you think Canada needs to prioritize to facilitate access? 
5. What do you think needs to be implemented for the sustainability of 















INFORMED CONSENT FORM FOR INTERVIEW PARTICIPATION 
 
 
Study Title:  Developing a system-level policy model for regenerative medicine and cell therapy 
in oncology 
 
Principal Investigator:   William Wong, PhD 
                                            Assistant Professor, School of Pharmacy,  
                                            University of Waterloo  
                                            Email: wwlwong@uwaterloo.ca 
                                            Telephone: 519-888-4567 ext. 21323 
Sponsor: BioCanRx Networks of Centres of Excellence 
 
INVITATION TO TAKE PART  
 
You are being asked to take part in this research study because you have experience with CAR T-
cell therapy (eg. as a researcher, clinician, pharmacist, lab personnel, policy maker, etc) and have 
a unique perspective. Before you decide if you would like to take part in this research, please 
read this information about the study and its risks and benefits. You should take as much time as 
you need to make your decision and ask the Research Coordinator to explain anything that you 
do not understand.  Make sure that all your questions have been answered before signing this 
consent form. Before you make your decision, feel free to talk about this study with anyone you 
wish. Taking part in this study is voluntary. 
 
 
BACKGROUND AND PURPOSE 
 
CAR T-cell therapy is a novel treatment in the cancer world. This cutting-edge therapy combines 
gene therapy and immunotherapy, and has demonstrated high efficacy in some relapsed or 
refractory hematological cancers. In 2017 there were two CAR T-cell therapies approved by the 
Food and Drug Administration (FDA) in the United States. In 2018, one of these, 
tisagenlecleucel (Kymriah) was approved by Health Canada for two indications.  At this stage, 
regenerative medicines such as  CAR T-cell therapy are costly and resource intensive, but offer 
the potential to cure some cancers. In the near future it is expected that Canada will have to 
make decisions regarding the adoption of CAR T-cell therapy, so it is important to conduct a 
health technology assessment by incorporating clinical evidence, cost-effectiveness analyses, 






The objectives of the study are to: 
1) Understand the capacity of the healthcare system to support the implementation of 
CAR T-cell therapy in Canada by learning about the processes of developing and 
delivering the treatment, and understand the current challenges associated with the 
implementation of this therapy. 
2) Develop a policy model and conduct an economic evaluation to estimate the health and 
economic burden of this therapy in the context of the Canadian healthcare system, and 
estimate the cost-effectiveness of the treatment compared to the current standard of 
care. 
   
The interviews will contribute valuable information to this project. Interviews with individuals 
who have various perspectives will be conducted to ensure that the qualitative evidence 
generated is representative of the current state of CAR T-cell therapy in Canada. Interviews will 




Participation in this study means taking part in one interview where we will ask you questions 
related to the following themes: 
1. To understand the processes of developing the CAR T-cell therapy, administering it to 
patients and monitoring them  
2. To understand the challenges or facilitators of the adoption of CAR T-cell therapy 
3. To understand how CAR T-cell therapy differs from other cancer treatments in terms of 
the resources required to develop and deliver it to patients, and how it will be assessed 
for reimbursement  
 
Taking part means that: 
 
1. You will participate in one interview either in person, over the phone or through 
video conferencing.  
2. The research coordinator will contact you and schedule the meeting at a convenient 
time. 
3. The interview will be audio recorded for analysis purposes. 
4. Anonymized quotations and information provided may be used in an environmental 




The interview will be about an hour in length. 
 
  






During the interview, you can tell the Research Coordinator about any feeling of discomfort you 
may have. You will not be forced to answer questions or to continue with the interview if you 





You may not receive direct benefit from being in this study. Information learned from this study 






Your participation in this study is strictly voluntary.  You may refuse to participate in any parts 
of the study.  You may decide to be in the study now, and then change your mind later. You 






If you decide to withdraw from the study, you have the right to request withdrawal of 
information collected about you, otherwise the information about you that was/were collected 
before you left the study will be used.  No new information about you will be collected without 
your permission. If you wish to withdraw from this study please contact the Study Coordinator 
Stephen Tully at 519-888-4567 ext. 21374. 
 
If you decide to withdraw from the study, would you give permission to use the data collected 




If you agree to join the study, the study team will collect only information needed for the 
organization of the interview: 
• Name 
• Address 
• Contact information 
• Profession 
 
Your identity will be kept confidential. Your name or any other identifying information will 
never be associated with the research data. The dataset without identifiers may be shared 
publicly.  You will not be named in any reports, publications, or presentations that may come 






When information is transmitted over the internet privacy cannot be guaranteed. There is always a risk 
your responses may be intercepted by a third party (e.g., government agencies, hackers). University of 
Waterloo researchers will not collect or use internet protocol (IP) addresses or other information which 
could link your participation to your computer or electronic device without first informing you. 
 
The sponsor will not be given access to your personal information. All personal information will 
be destroyed at the end of the study.   
 
 
COSTS, REIMBURSEMENT, AND COMPENSATION 
 
We anticipate you will not have any extra expenses for taking part in this study.  
 
 
CONFLICT OF INTEREST: 
 
This study has been funded by BioCanRX. The researchers have no conflict of interest to report. 
The researchers have an interest in completing this study. Their interests should not influence 
your decision to participate in this study. 
 
QUESTIONS ABOUT THE STUDY: 
 
This study has been reviewed and received ethics clearance through a University of Waterloo 
Research Ethics Committee (ORE# 23163). If you have questions for the Committee contact the 
Office of Research Ethics (ORE), at 1-519-888-4567 ext. 36005 or ore-ceo@uwaterloo.ca.  
If you have any questions, concerns or would like to speak to the study team for any reason, 
please call: Stephen Tully, the study coordinator, by email at stully@uwaterloo.ca, or phone at 
519-888-4567 ext. 21374, or the principle-investigator William WL Wong at 
wwlwong@uwaterloo.ca, or 519-888-4567 ext. 21323.  





CONSENT TO PARTICIPATE IN INTERVIEW 
 
 
This study has been explained to me and any questions I had have been answered. I know that I 
may leave the study at any time. I agree to the use of my information as described in this form. 








________________________________________      ___________________ 
Signature of Participant                                                     Date 
 
 
My signature means that I have explained the study to the participant named above. I have 








________________________________________      ___________________ 

















Table A2. Code List for Qualitative Analysis 
Category/Theme Code Definition 
Novel Novel, personalized 
therapy, not a drug 
It’s difficult to classify CAR T-cell therapy. It’s not a drug. 
It’s personalized. It doesn’t fit into typical classifications. 
Novel Novel development, 
evolving, cell and gene 
therapies require 
innovation in healthcare 
system  
CAR T-cell therapies and others are evolving but the 
current government and hospitals systems are inflexible, 
which makes it challenge  
Novel Long-term survival - 
curative 
Novel in ability to cure 
Novel Access, healthcare policy, 
infrastructure 
Novel in the additional resources required 
Unmet need Unmet need Patients have no other treatment options at the stage they 
need CAR T-cell therapy 
Equity  Ensuring equitable access Will be difficult to provide equal access across country 
(e.g., Toronto vs. PEI). Need to have systems to plan for 
people who are not located near a CAR T-cell site. CAR T 
won’t be offered in all provinces, only specific centres 
Future state Sustainability If the indications grow, how will it be made more broadly 
available? It will likely replace some current standards of 
therapy, but how can provinces afford multiple new 
breakthrough drugs? 
Manufacturing Manufacturing model Can be manufactured industrially or in academic setting 
Manufacturing Manufacturing process - 
lentivirus 
How the lentivirus created 
Manufacturing Manufacturing process – 
patients  
Obtaining cell samples from patients 
Capacity  General Doesn’t fit into one category, problems with demand 
Capacity  Government and 
regulatory 
Governments and regulatory agencies need to be able to 
review and make decisions about these emerging cell and 
gene therapies 
Capacity Hospital resources Need beds (i.e., infusion, ICU). Can be expanded/built in 
centres who already have capacity for stem cell and bone 
marrow transplant. Challenge in provinces who won’t be 
able to have this capacity (i.e., PEI).  
Capacity Health human resources Personnel required to deliver CAR T 
Capacity Manufacturing facilities Need enough facilities to satisfy demand; facilities that can 
abide by Good Manufacturing Practices 
Capacity Manufacturing human 
resources 
Who is needed to manufacture CAR T 
Problems Error in 
manufacturing/quality 
control 
It can happen when making the lentivirus (but quality 
control catch this), contamination of batch  
Problems Patient health status and 
cell sample 
When patients cannot provide a good sample of T-cells 
Problems Infusion/administration of 
CAR T-cell 
Very unlikely to have a problem or error during infusion. 
Could be infused as an outpatient and doesn’t require 







Funding At the moment there is no funding in Canada, which means 
patients are going to the US to access treatment. Who pays? 
It’s out of scope of the provincial drug program budgets. A 
budget must be established. 
System level 
planning 
Infrastructure-hospital  Ensuring manufacturers/hospitals have sufficient tools to 
manufacture a product on site. Needs to have redundancy. 




Training Ensuring technicians running machines, clinicians who give 
treatment, GMP employees have proper training. 
System level 
planning 
Hospital care Ensuring hospitals have capacity to care for patients after 
infusion. Can rely on past programs that are large and 
stable—will need to use the same policies. 
-ICU beds  
System level 
planning 
Leadership Who leads implementation in Canada? Includes CCO, 
pCPCA mentioned as having experience with these types of 




Planning - data 
management 
(infrastructure needed) 
Data needs to be collected, sorted, analyzed, and used to 
make decisions about future steps and to assess the current 
systems of reimbursement, cost of treatment delivery, 
measuring quality, measuring outcomes. 
System level 
planning 
Regulatory Planning through CCO, PCPA, approval process, reviewing 
cases, relationship between drug companies and 
government and hospitals 
System level 
planning  
Coordination Logistics, institutions working together (manufacturer, 
government, hospitals), collaboration 
Time Bedside to bench to 
bedside 
Time for leukapheresis, shipping, manufacturing CAR T in 
Prodigy machine, shipping, prepping patient, administering 
to patient, aftercare 
Time Manufacturing 2-3 weeks in manufacturing. Need to move to point of care 
model where manufacturing happens on site, not 
industrially. 
Time Patient waiting  Patient knows they are getting CAR T – time when CAR T 
is being manufactured and they need to remain stable 
Time Reimbursement approval 
time and price negotiation 
time 
Regulatory – time for assessment if drug will be reimbursed 
– either for each individual patient or generally by CADTH 
Time In hospital during 
treatment /monitoring 
After infusion, in hospital, adverse events 
Cost To system Talked about broadly, can’t categorize 
Cost CAR T-cell products Current CAR T cell therapy is unaffordable. Very 
expensive, cost will limit use. 
Cost Hospital Need to account for hospital and healthcare provider costs 
Cost  Pricing, cost-effectiveness 
and value 
Needs to be negotiated with the manufacturer to bring cost 
down to be affordable for the healthcare system and cost-
effectiveness need to be established before implemented 
and re-evaluated because of uncertainty in data 
Evidence  Limited evidence Efficacy, effectiveness (mostly these 2 but also limited 






There is uncertainty about the effectiveness of CAR T-cell 
therapy, which makes it difficult to make decisions (i.e., 
policy, clinical, etc). Many clinical trials happening now 
which may point to new indications. Lacking long-term 
data. 
Evidence Emerging evidence  Place in therapy (moving up to earlier lines), new 
indications for CAR T, new drugs other than CAR T for 
cancer 
Includes: How does the system act on new evidence? Will it 
be a last resort or the standard of care.  
Specifically mentions emerging evidence but doesn’t use 
novel 
Patient eligibility Patient eligibility/patient 
population criteria – 
current (General 
characteristics) 
Currently, it is for adult and pediatric ALL and DLBCL, 
when patients have failed bone marrow transplant or cannot 
receive a BMT, and usually the only other treatment option 
is palliative. No age limit but patient needs they need to be 
physically well enough to tolerate it (i.e., no organ failure) 
and have T-cells that can be harvested. 
Patient eligibility Patient eligibility – 
Exclusion 
Who actually gets treatment. You may not get treatment if 
you are too old (80-90), cancer is too aggressive, don’t have 
T cells. 
Patient eligibility Patient eligibility – access, 
healthcare policy 
Who determines who has access to and coverage for CAR 
T-cell therapy, and the timing of when that decision occurs 
after the request. 
-Evaluating case by case 
-Describing # of cases and impact on system 
-Access in Canada vs U.S. 
Patient eligibility  Specific indication for 
therapy  
After 2 failed lines of therapy, refractory/relapsed 
Patient 
experiences 
Current burden of 
treatment process on 
patient 






events (collapsed with 
Process-Adverse events) 
Cytokine release syndrome, infection, CNS toxicity (ranges 
from minor to fatal), late cytopenias. More manageable 





What is the patient’s disease course (dismal at this point), 
how will the treatment alter the disease course. 
-Describing treatments patients will get and in what order 
Process Storing, shipping, 
transport 
Cell product storage and how/when it is shipped and how it 
is transported 
Process Preparing the patient Patients need to have chemotherapy beforehand. Challenge 
is in keeping patient well enough from leukapheresis to 
CAR T-cell infusion.  
Process Infusion Describing how this process works 
Process Monitoring How patient is infused with CAR T-cells, monitored for 
side effects as an inpatient and outpatient. 
Similar To 
Transplant 





Table A3. Patient characteristics in ZUMA-1, SCHOLAR-1 and JULIET trials 
Patient Characteristic ZUMA-1 SCHOLAR-1 JULIET 
Median Age 58 years 55 years 56 years 
DLBCL, Primary 
mediastinal, follicular 






26% 28% Refractory DLBCL: 
55% 
Received 3 prior 
therapies 
69% <1% (49% received 2 
prior lines) 
31%  
Disease relapse after 
transplantation 
21% 22% (less than 12 
months post transplant) 
 
Disease resistant to 
second or late line 
therapies 
77% 50%   
Stage III or IV disease 85% 72%  76% 
Previous autologous 
SCT 
21% (ICER) 22% (ICER) 49%  
Percentage who 
received SCT after 
CAR T 
 
11% (Roth-need to find 
source) 
27%  
Bridging chemotherapy Systemic bridging 







CRS – any  93% N/A 58%  
CRS –Grade 3 or 
higher 
13% N/A 22% 
Neurotoxicity – any  64% N/A 21%  
Neurotoxicity -Grade 3 
or higher 










Figure A.3. Axicabtagene ciloleucel – PFS – Parametric distributions 
 
 Loglogistic Weibull Lognormal Gamma Exponential 
AIC 392.779 411.229 388.534 416.957 423.254 
BIC 398.198 416.648 393.953 422.376 425.963 
 
Figure A.4. Tisagenlecleucel – OS – Parametric distributions 
 
 Loglogistic Weibull Lognormal Gamma Exponential 
AIC 404.192 411.229 388.534 416.957 423.254 






Figure A.5 Salvage chemotherapy OS – Parametric distributions – based on 3 years of data using ECOG 1 
and 2 patients 
 
 Loglogistic Weibull Lognormal Gamma Exponential 
AIC 1582.236 1646.993 1578.242 1654.280 1654.065 
BIC 1589.506 1654.262 1585.512 1661.550 1657.700 
 






Figure A.7. Validation of extrapolation of axicabtagene ciloleucel OS curve 
 
Figure A.8. Validation of extrapolation of salvage chemotherapy OS curve 
 
